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Abstract
Members of the Runx family of transcription factors play essential roles in the
differentiation and development of several organ systems. Here we address the
contribution of the osteoblast-related Runx gene Runx2 to the osteogenic and
chondrogenic differentiation of mesenchymal stem cells. Using a transgenic mouse
model, we observe Runx2 transcription through one of its two known promoters
(designated PI in pre-carilaginous mesenchymal condensations as early as E9. 5. Runx2
gene activity is later repressed at the onset of cartilage formation, both in vivo and 
vitro necessitating examination of the regulation and fuction of Runx2 in mesenchymal
stem cells. We demonstrate that Runx2 gene activity is repressed by the direct interaction
of the homeodomain transcription factor Nkx3.2 with the proximal Runx2 PI promoter.
This repression was found to be required for the progression of BMP-induced
chondrogenesis, thereby identifying Runx2 as a modulator of BMP activity in the
chondrogenic as well as osteogenic differentiation program. To further understand the
regulation of the Runx2 PI promoter and to determine the contribution of PI-derived
gene product, Runx2 Type II , to the formation of mineralized tissue, we have generated a
Runx2 Type II- LacZ gene replacement mouse model in which the initial coding
sequences and splice donor sites of the Type II isoform are replaced with the LacZ
reporter gene. Activity of the endogenous PI promoter can therefore be monitored by (3-
galactosidase production. Analysis of Runx2 Type II-LacZ mice demonstrates that the
PI promoter is transcriptionally most active in mature osteoblasts
, but its product, Runx2
Type II is dispensable for embryonic skeletal formation. Lastly, we examine the link
between growth control and osteogenic differentiation by tissue-specific deletion of the
Mdm2 proto-oncogene in developing skeletal tissues of the mouse embryo. Loss of
Mdm2 results in impaired bone formation, with skeletal elements exhibiting lower bone
mineral content and higher porosity. Ex vivo cultures of calvarial osteoprogenitor cells
exhibit severely decreased osteoblastogenesis and bone nodule formation accompanied
by a failure to activate Runx2 gene activity. These findings suggest that Mdm2 is
required for inhibition of p53 activity that ultimately allows for post-confluent
proliferation and induction of Runx2 during maturation of the osteogenic phenotype.
Taken together, our findings suggest that Runx2 modulates the commitment of progenitor
cells to the osteogenic and chondrogenic lineages, and that Run2 activity is inextricably
linked to mechanisms that control cellular proliferation.
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Chapter I: General Introduction
Ji-.
Skeletal Formation
Formation of the vertebrate skeleton is an exquisitely intricate process that requires the
coordinated proliferation, migration, and differentiation of a variety of cell types
including the cartilage-forming chondrocyte , the bone-forming osteoblast, and the bone-
and cartilage-resorbing osteo/chondroclast. During mammalian development, the
mesenchymal cells that form the skeleton are derived from distinct embryonic origins.
Neural crest cells contribute to the skull and craniofacial bones
, lateral plate mesodermal
cells form the appendicular skeleton (limbs and extremeties), and sclerotomal cells
derived from the somites give rise to the axial skeleton (spine and ribs) (Figure 1. I-A).
Despite the distinct embryonic lineages that contribute to skeletal formation
, there are
similarities in function and gene expression in the skeletal cells derived from these
lineages and these cells all participate in several phases of skeletogenesis. Initially,
mesenchymal progenitor cells migrate to sites of skeletogenesis
, then undergo epithelial-
mesenchymal interactions which in turn induce condensation that is followed by overt
differentiation either directly into bone-forming osteoblasts (a process termed
intermembranous bone formation occurring primarily in the craniofacial skeleton in
which there is no carilaginous template for the future bone) or into chondrocytes which
wil go on to form a carilaginous template for future bone formation (Figure 1.1-B).
Bone formation following a cartilaginous template occurs in the majority of the skeleton
through a process termed endochondral bone formation. During endochondral bone
formation, the mesenchymal condensations that occur at sites of future bone formation
neural tube
I ..
\ / '''.. . \\.. 
- dermatome
endoderm .
. -
notochord
'- 
myotome
, i
Migration Epithelial-mesenchymal
interaction
Condensation Differentiation
Figure 1.1: Mesenchymal progenitor cells of the somites are
induced to differentiate into sclerotome, myotome, and
dermomyotome in response to local signallng molecules secreted
from the notochord. Cells of the sclerotome are destined to
undergo chondrogenesis and form the cartilaginous template for
the components of the axial skeleton (A). Mesenchymal progenitor
cells undergo several phases of skeletal development. These cells
migrate. then undergo epithelial-mesenchymal interactions which
induce condesation. Ultimately, these cells undergo differentiation
into the various cell types that comprise the mammalian skeleton
(B). Adapted from Principles of Bone Biology by JP Bilezikian , LG
Raisz and GA Rodan, Academic Press. 2002.
undergo overt chondrogenesis rather than osteogenesis thereby gIvmg rise to 
cartilaginous anlage for future mineralization. This temporary cartilage subsequently
undergoes a maturation process termed hypertrophy in which the chondrocyte cell body
expands and the cartilaginous extracellular matrix is mineralized (the molecular pathways
governing these processes are discussed in detail in chapters 2 and 3). This mineralized
cartilage is then invaded by vasculature that carries both bone/cartilage-resorbing
osteo/chondroclasts as well as precursors of bone-forming osteoblasts to the site of new
tissue formation. It is the coordinated activity of these two cell types that ultimately leads
to the formation of mineralized bone on the existing cartilaginous template. Bone
forming osteoblasts differentiate in situ where they deposit a number of extracellular
matrix proteins (primarily type I collagen) that comprise the organic component of the
mineralized skeleton. Subsequently, the osteoblast wil deposit crystallne salts into the
extracellular matrix (primarily calcium and phosphorous in the form of hydroxyapatite)
in order to mineralize the organic matrix and provide rigidity to the system. In the past
decade, many studies aimed at understanding the genetic activity that underlies these
processes have culminated in the discovery and functional characterization of the Runx2
gene, whose product is emerging as the single most important protein in the complex
process that is skeletogenesis.
Biology of Runx Proteins
Runx2 is a member of the mammalian family of Runt-related transcription factors that
consists of three proteins that share the DNA-binding Runt-homology domain. Genetic
,,-
analysis of mIce harboring targeted inactivating mutations in these genes has
demonstrated their importance in organogenesis as well as cell growth control. Runx 1
deficiency leads to early embryonic lethality due to failed hematopoesis (North et al.
1999; North et al. 2002); Runx2 deficiency results in a block in osteoblast differentiation
and a total lack of mineralized tissue (Ducy et al. 1997; Komori et al. 1997; Otto et al.
1997); and Runx3 deficiency leads to impaired neuronal development and hyperplasia of
the gastric mucosa (Levanon et al. 2002; Li et al. 2002). Although these findings clearly
demonstrate the importance of the Runx transcription factors in development of specific
tissues, recent evidence indicates that the role of the Runx proteins is more complex. The
co-expression of multiple Runx factors in several early embryonic tissues suggests a
fuctional redundancy that is supported by recent evidence demonstrating the cooperation
ofRun2 and Runx3 in carilage maturation (Taniuchi et al. 2002; Yamashiro et al. 2002;
Yoshida et al. 2004). Here we focus on the regulation and function of the Runx2 protein
during fate determination in progenitor cells , and also examine some functional
interrelationships between Run and Runxl.
Properties and Functions of Runx2
Runx2 was originally identified as an inappropriately activated gene in virus-accelerated
T -cell lymphomas. Deregulation of Runx2 expression was found to be a consequence of
retroviral insertion into the Runx2 promoter region (Stewart et al. 1997). Further studies
from the Stewart group demonstrated that Runx2 overexpression in T -cells results in
spontaneous tuor formation in transgenic mice that can be synergistically accelerated in
the presence of a myc transgene , revealing the oncogenic potential of Runx2 (Vailant et
al. 1999). Shortly thereafter, Runx2 was identified independently as a major DNA
binding component on the bone-specific osteocalcin promoter
, indicating that the normal
function of Runx2 is related to osteoblast differentiation (Banerjee et al. 1997). In 1997
two groups independently generating Runx2 null alleles confirmed the importance of
Runx2 in osteogenesis as null mice arising from these targeted mutations lacked matue
osteoblasts and a mineralized skeleton (Ducy et al. 1997; Komori et al. 1997; Mundlos et
al. 1997; Otto et al. 1997). Interestingly, Runx2 null mice successfully form a
cartilaginous template for the skeleton
, but lack subsequent vascular invasion and
turnover of cartilage into bone. Runx2 haploinsufficiency results in a disease in mice that
is analogous to the human disorder Cleidocranial Dysplasia (CCD), a disease
characterized by supernumerar teeth, defective cranial suture ossification resulting in
delayed fontanel closure , and absent or hypoplastic clavicles (Mundlos et al. 1997).
Indeed, a variety of mutations in the Runx2 gene have been mapped in CCD patients
(Mundlos et al. 1997; Y okozeki et al. 2000; Zhang et al. 2000; Bergwitz et al. 2001;
Goseki-Sone et al. 2001; Ito and Zhang 2001; Golan et al. 2002; Otto et al. 2002;
Vaughan et al. 2002; Yoshida et al. 2002; Tessa et al. 2003). Molecular analysis of
Runx2 function ultimately demonstrated that Runx2 is able to transactivate a plethora of
osteoblast phenotypic genes (alkaline phosphatase, MMPs, type I collagen, osteocalcin,
Osterix) necessary for proper bone formation. Further
, Runx2 acts as a scaffolding
protein within the nucleus through its nuclear matrix targeting signal (NMTS). The
NMTS is a conserved 31-38 amino acid motif that directs Runx2 to distinct nuclear
domains that support gene expression (Zaidi et al. 2001; Zaidi et al. 2002) and deletion of
this domain along with the C-terminus of Runx2 results in a phenotype analogous to that
seen in Run null mice (Choi et al. 2001), suggesting that proper subnuclear targeting is
required for the functional activity of this protein in promoting osteoblast differentiation.
More recently, findings from Pratap and Galindo (Pratap et al. 2003) have uncovered a
role for Runx2 in growth control. They demonstrated that Runx2 levels are stringently
regulated with respect to cell cycle entry and exit of osteoprogenitor cells and that these
cells exhibit higher proliferation rates in the absence of Runx2. Taken together, these
findings suggest that Runx2 supports differentiation of the osteoprogenitor not only
through the direct activation of osteoblast phenotypic genes but also by supporting exit
from the cell cycle.
Runx and the Mesenchymal Stem Cell
Despite the extensive body of literature relating to the function of Runx2 in osteoblast
differentiation, little is known about the function or regulation of this gene in the stem
cell population that gives rise to osteoblasts, chondrocytes, adipocytes, myoblasts, and
fibroblasts. These cells are termed mesenchymal stem cells (MSC) and are derived from
the embryonic mesenchyme. For the purposes of this dissertation, we wil focus on the
embryonic mesenchyme that makes up the somites that in turn give rise to the axial
skeleton through the process of endochondral bone formation. The basic anatomic
blueprint during embryogenesis is derived from the segmentation of paraxial mesoderm.
Upon gastrulation, these cells segregate to form the presomitic mesoderm that surrounds
the neural tube on either side. Through the actions of a number of homeodomain (Hox),
and pair-rule (hairy, lunatic fringe) transcription factors, the unsegmented presomitic
mesoderm becomes segmented in a series of paired condensations called somites. During
somitogenesis, segmentation occurs sequentially by the addition of new so mites in a
craniocaudal manner with a periodicidy that reflects the segmental organization of the
embryo. The somites later respond to a number of soluble signaling molecules secreted
by the notochord (particularly Sonic hedgehog and Wnt) by undergoing further
segmentation into myotome, dermomyotome, and sclerotome , each of which in turn gives
rise to specific mesenchymal tissues (Figure 1. I-A). Activation of all thee Runx genes 
apparent during somitogenesis and persists during formation of the sclerotome. The
mesenchymal progenitor cells in the scelerotomal condensations are destined to give rise
to the carilaginous template of the axial skeleton in response to the activity of a number
of transcription factors including members of the Pax, Sox, and Nk families. The
fuction of Run factors during this developmental stage is entirely unkown as deletion
of anyone Runx protein has no effect on the formation of somites, sclerotome , or the
cartilaginous template during endochondral bone formation. It is this observation that
has driven the work described in this dissertation in which the function and regulation of
f::"
Runx2 are examined in the mesenchymal progenitor cell, and a link between growth
control and differentiation into skeletal cells is established through Run2.
Aims of the Dissertation
While significant progress has been made in understanding the functional activity of
Runx2 , relatively little is known about the regulation of this gene. Initial studies on the
Runx2 promoter by Drissi et al. demonstrated that Runx2 activity was suppressed by the
osteogenic steroid hormone vitamin D3 as well as by autoregulatory activity in osteoblast
cell lines (Drissi et al. 2000; Drissi et al. 2002a; Drissi et al. 2002b). This dissertation is
aimed at elucidating pathways that regulate the Runx2 gene during skeletogenesis and
understanding the fuctional consequences of this regulation.
In the subsequent chapters, we address the transcriptional regulation of the Runx2 gene in
the developing mammalian embryo using a combination of in vivo and in vitro
approaches. We identify a region of the bone-related Runx2 promoter that appears to be
highly active in pre-chondrogenic mesenchymal condensations of the axial skeleton in
the developing murine embryo and we show that the Runx2 promoter is negatively
regulated by the pro-chondrogenic NK-domain homeobox transcription factor Nkx3.
Our data suggests that the negative regulation by Nkx3.2 acts to suppress anti-
chondrogenic properties of Runx2 , thereby promoting chondrogenic differentiation of
mesenchymal progenitor cells.
Next, we examine the temporal expression patterns and functional contributions of both
Runxl and Runx2 throughout the differentiation of mesenchymal progenitor cells into
mature chondrocytes. To this end, we have developed an ex vivo culture system in which
mouse embryonic fibroblasts (MEFs) are induced to undergo chondrogenesis in response
to high-density culture conditions and bone morphogenetic protein-2 (BMP2) signaling.
The ability to isolate MEFs mid-gestation enables the study of Runxl gene function
during the development of the chondrogenic phenotype ex vivo for the first time due to
the early, pre-carilaginous embryonic lethality of mice with inactivating mutations in the
Runxl gene. We observe that MEFs lacking Runxl are able to undergo the complete
program of chondrocyte differentiation, while MEFs lacking Runx2 are able to form
chondrogenic masses ex vivo, but cannot undergo final stages of hypertrophy. Furher
we show that in absence of Runx2 , Runx 1 protein levels are unaltered, suggesting that
minimal cross-regulation occurs in during this process. Our findings further demonstrate
that although both Runxl and Runx2 genes are active in these cells, they exhibit unique
expression patterns suggesting that Runx 1 and Runx2 may have the capacity to play
unique roles during the growth and differentiation of a single cell type.
The fifth chapter of the dissertation is aimed at exploring the contribution of the Runx2
Type II isoform to the process of osteogenesis. This isoform, termed Type II , or til, is
under control of the upstream PI promoter and exhibits a much more restricted
expression pattern in comparison to its downstream counterpart, Runx2 Type I (Park et
al. 2001; Chen et al. 2002; Choi et al. 2002). These two proteins differ only in that the
Type II isoform contains an additional 19 amino acids at its N-terminus. Despite these
additional amino acids, the Runx2 isoforms appear to fuction identically with regards to
their ability to transactivate target promoters (Banerjee et al. 2001) indicating functional
redundancy between these proteins. These observations suggest the importance of the two
promoter regions at the Runx2 locus may be to gain another level of control of Runx2
expression during different developmental circumstances. To address the specific
fuction of the Type II isoform and the bone-specific activity of the PI promoter, we
have engineered embryonic stem cells and subsequently generated a mouse line
containing a targeted gene knockin in which the lac- reporter gene replaces the initial
exon unque to Runx Type II. This targeting strategy enables us to monitor endogenous
gene activity at the PI locus by X-Gal staining while maintaining expression of Run2
Type I through the downstream P2 promoter. Our results demonstrate that Runx2 PI
promoter appears to be most active in the most mature osteoblasts along cortical bone
surfaces in vivo and in the center of mineralizing osteoblast nodules ex vivo. Preliminary
phenotype analysis of Runx2 Type II -/- mice is underway despite a published report
which indicates that loss of this isoform results in defective formation of a variety of
skeletal elements and a surprisingly high rate of perinatal lethality (Xiao et al. 2004).
The final portion of the dissertation establishes a novel link that exists between bone
formation , Runx2, and the proto-oncoprotein Mdm2. Mdm2 is well known for its
fuction as a critical regulator of p53. By inactivating p53 through several mechanisms
Mdm2 allows for progression of the cell cycle in many primary and immortalized cell
lines. Here we examine the contribution of Mdm2 to skeletogenesis by utilizing an
Mdm2 conditional allele generated by Dr. Heather Steinman (Steinman and Jones 2002).
We achieved tissue-specific deletion of Mdm2 in the developing skeleton by
interbreeding Mdm2 conditional mice to transgenic mice harboring the Cre-recombinase
gene under control of the type I collagen promoter (kindly provided by Dr. Barbara
Kream at the University of Connecticut). Our findings demonstrate that an increase in
Mdm2 activity during osteoblast maturation is required to suppress p53 activity in order
for pre-osteoblasts undergo cell division in post-confluent 
ex-vivo cultures. Upon deletion
of Mdm2 , pre-osteoblasts fail to form multilayered nodules and subsequently fail to
induce Runx2 ultimately resulting in a block in differentiation. These results suggest that
pathways governing growth control and differentiation are intricately intertwined in the
osteoblast and must be coordinated for the successful establishment of the mammalian
skeleton.
Taken together, our findings ilustrate the complexities of Run biology and highlight the
importance of Runx2 in the development of multiple mamalian tissues. The proceeding
findings of this doctoral thesis offer important insight into the complex regulation and
functionality of Run2 and establish a basis for future research into novel functions of the
Run family of proteins.
---
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Chapter 
Activation of the Bone Related Runx2/Cbfal Promoter in
Mesenchymal Condensations and Developing
Chondrocytes of the Axial Skeleton
ABSTRACT
The Runx2/Cbfal transcription factor is expressed at early stages of embryonic
development and is required for bone formation. Elucidating the transcriptional
mechanisms that support the developmental function of Runx2 is important for
understanding the signals mediating skeletal formation. In this study, we examine the
spatio-temporal activity in vivo of the Runx2 PI promoter that controls expression of the
bone related isoform. Transgenic mice caring 3 kb of the Runx2 promoter fused to the
LacZ reporter gene exhbit localized promoter activity that parallels the endogenous gene
in early mesenchymal condensations shortly after the embryonic turning event.
Expression in developing mesenchyme continues throughout the differentiation of these
cells into chondrocytes at later embryonic stages and is restricted to the axial skeleton.
Taken together, our data support a function for Runx2 in establishment of the
prechondrocytic skeleton.
INTRODUCTION
Skeletal formation is a multistep process initiated by condensations of mesenchymal
precursor cells that wil form the skeletal architecture through both intramembranous and
endochondral ossification. The events leading to the development and formation of
osseous tissue are governed by a variety of signaling pathways and regulatory factors
including hormones, growth factors, cytokines, and transcription factors. Several
transcription factors including members of the homeodomain family are required for
epithelial-mesenchymal interactions and early skeletal patterning (Thesleff 1998; Olsen
et al. 2000; Hall 2001). Runx2 , a member of the runt-homology domain family of
transcription factors, is the only transcription factor known to be necessary for the
formation of the entire mineralized skeleton (Komori et al. 1997; Otto et al. 1997; Choi et
al. 2001).
Runx2 shares strong homology with the Drosophila pair-rule genes runt and lozenge that
playa role in body patternng (Canon and Banerjee 2000). In mamals, the Runx genes
(Runxl , Runx2 and Runx3) have essential roles in organ development. Runx) is required
for proper hematopoiesis (Okuda et al. 1996; North et al. 1999), Runx3 is important for
gut development (Levanon et al. 2002; Li et al. 2002), whereas Runx2 is essential for
skeletal formation. Haploinsufficiency of Runx2 results in cleidocranial dysplasia (CCD)
both in humans and mice (Ducy et al. 1997; Komori et al. 1997; Mundlos et al. 1997;
Otto et al. 1997), and targeted disruption of the Runx2 locus causes a total lack of bone
formation due to the maturational arrest of osteoblasts (Choi et aI. , 2001; Komori et aI.
1997; Otto et aI. , 1997). Runx2 regulates both osteoblast (Banerjee et aI. , 1997; Ducy et
aI., 1997) and chondrocyte (Akiyama et ai. 1999; Inada et ai. 1999; Kim et ai. 1999;
Enomoto et al. 2000; Takeda et al. 2001; Ueta et ai. 2001) maturation and thus
, the Runx2
gene must be responsive to both chondrogenic and osteogenic signaling pathways.
The Runx2 locus encodes two principal isoforms that are transcriptionally controlled by
two distinct promoter regions. The Type I Runx2 isoform (initiating with the peptide
sequence MRIPV) is expressed in a variety of cell types including cartilage and bone
(Kim et al. 1999; Banerjee et al. 2001) and is regulated by a downstream promoter (P2).
The Type II isoform (initiating with the peptide sequence MASNS) was originally cloned
as Cbfall til- l (Stewar et al. 1997) and is under the control of an upstream (PI) promoter
(Fujiwara et ai. 1999; Drissi et ai. 2000; Xiao et al. 2001). This isoform is highly
expressed in differentiating osteoblasts and is upregulated in response to the osteogenic
BMP-2 signal (Enomoto et al. 2000; Banerjee et ai. 2001).
We have previously reported the cloning and characterization of the bone related Runx2
PI promoter and have identified consensus binding sequences for a number of well
known transcriptional regulators including NFkB , API family members , C/EBP, steroid
receptors, as well as helix loop helix proteins. Interestingly, the promoter contains
functional Runx2 and Vitamin D binding sites that both suppress Runx2 promoter activity
(Drissi et ai. 2000; Drissi et ai. 2002a). Understanding promoter regulatory mechanisms
that mediate skeletal specific expreSSIOn 
of Runx2 will provide insight into the
requirements for activity and regulation ofRun2 function in skeletal development.
This study addresses the in vivo contributions of a 3 kb segment of the 
Runx2 promoter to
the highly specific spatio-temporal events that occur in the process of skeletal formation.
The activity of a Runx2 PI promoter-LacZ transgene (3 kb-LacZ) was assessed by the
detection of the f)-galactosidase enzyme throughout the development of the mouse
embryo. Consistent with the onset of expression of 
endogenous Runx2 this promoter
confers regulatory information activating transgene expression in early 
mesenchyme
shortly after the embryonic turning event. The transgene continues to express in the
perichondrium and in cells of the chondrocytic lineage in the axial skeleton
, but is absent
from chondrocytes of the appendicular skeleton and from cells of the osteoblastic lineage.
Taken together
, these results indicate that the promoter of the bone related 
Runx2 gene
contains regulatory information that supports expression in 
early mesenchymal
condensations and specifies temporal and skeletal site selective activation.
MATERIALS AND METHODS
Plasmids
The transgenic vector (Runx2-LacZ) was constructed using a 2.9 kb Bgl II/Pst I fragment
from the 5' flaning region of the Runx2/til- bone related isoform (Figure 2. A) ligated
into the pBluescript SK + backbone vector (Stratagene
, La Jolla, CA). The bacterial LacZ
gene (f)-galactosidase) carring a bovine growth hormone poly-adenylation signal (kindly
provided by Dr. Stephen Jones, University of Massachusetts Medical School) was then
ligated at the immediate 3' end of the promoter fragment into a PstI/XhoI site of the
pBluescript poly linker region. In transient transfection assays
, a CMV LacZ construct
was used to control for transfection effciencies.
Transfection Experiments
ROS 17/2.8 osteosarcoma cells were cultured in F12 media in the presence of 10% fetal
calf serum, 2 mM L-glutamine , penicilin/streptomycin, and were maintained in a
humidified 37 incubator with 5% CO ROS 17/2. 8 cells were transiently transfected
using Superfect lipofection reagent (Qiagen, Valencia, CA) in 6 well plates 24 hours after
seeding cells at a density of 10 cells per well. The transfection complex was formed
using either 2 !lg of the Runx2-LacZ construct or 0. 5!lg ofCMV-LacZ construct along
with carrier DNA for efficient transfection and 8 mLiwell of Superfect lipofection
reagent in one tenth of the final feeding volume of incomplete DMEM. The cells were
then incubated for three hours with the superfect/DNA complex before washing and
feeding with fresh completed F12 media. After transfection, cells were incubated for 48
hours and f)-galactosidase activity was assessed qualitatively by X-gal staining cells fixed
for 5 minutes in 0.5% glutaraldehyde (EM Sciences, Gibbstown, NJ) with the X-gal
substrate solution containing 2 mM MgCh, 5 mM potassium ferrocyanide , 5 mM
potassium ferricyanide , 0.01 % sodium deoxycholate , 0.02% NP- , and 1 mg/mL X-gal
(5-bromo-4-chloro- indolyl-f)-galactopyranoside, Gold Biotechnology, St Louis , MO) in
phosphate buffered saline (PBS , pH 7.3) at room temperatue for 10- 12 hours.
Generation of Transgenic Mice
The transgenic construct was digested with Not I/Xho I in order to linearize the transgene
and remove the backbone vector. The resulting digestion products were
electrophoretically separated and the linearized transgene was purified using a gel
extraction kit (Qiagen, Valencia, CA). Microinjection of the linearized transgene into
fertilized oocytes from C57/BL6xSJL mice (Jackson Labs
, Bar Harbor, ME) and transfer
of microinjected embryos into pseudopregnant foster mothers was performed by the
Transgenic Animal Core Facility at the University of Massachusetts Medical School.
Animals were maintained and used in accordance with the Federal Animal Welfare Act
and the NIH Guide for the Care and Use of Laboratory Anmals under the supervision 
the Institutional Animal Care and Use Committee at the University of Massachusetts
Medical School. The injections resulted in 65 potential founder mice, 9 of which were
found to carr the transgene. Of these nine founder mice, two mice that expressed the
transgene were mated to generate transgenic lines (L 1 & L2) for analysis.
Genotyping
Genotyping was carred out using Southern blot analysis and PCR with primers spanning
the Runx2 promoter/LacZ junction (Fig. 2C). Genomic DNA was isolated from mouse
tail clips by digestion with proteinase K followed by phenol-chloroform extraction and
ethanol precipitation. For Southern blot analysis (Figure 2.2-
C), 10 g of genomic DNA
was digested with Sac I
, releasing a 3 kb fragment spanning the promoter/ LacZ junction.
Digested DNA was electrophoresed in a 1% agarose gel, transferred onto a nylon
membrane , and hybridized with an 1100 bp p labeled cDNA probe spanning the
promoter/ LacZ junction (Figure 2.2-A). PCR analysis was performed on 100 ng of
genomic DNA using forward primer 5' GGAGAGACAGAGGAACACCCATAAG3' and
reverse primer 5'CGTGGGAACAAACGGCGGATTGA3' using 29 cycles of one minute
at 94 , one minute at 60 , and one minute at 72 . Resulting PCR products were then
electrophoresed in a 1 % agarose gel and assessed by ethidium bromide staining.
In vivo analysis of transgene expression
Embryos were harvested from timed pregnant mothers at two-day intervals. Timed
pregnant mothers were sacrificed by cervical dislocation after being anesthetized by
isoflurane inhalation. Whole embryos were removed from the mother and fixed in a
solution containing 2% paraformaldehyde, 0.2% glutaraldehyde, 5 mM EGT A, 2 mM
MgCh, and 0. 1 M PBS from 1 hour to overnight, depending on the size of the embryo.
Whole embryos were then stained for f)-galactosidase activity or frozen in TBS tissue
freezing medium (Triangle Biomed. Sci. , Durham, NC) on dry ice after overnight
equilibration in 30% sucrose for sectioning in a cryostat (Model OTF , Bright Instruents
Huntingdon, UK). Ten m sections were cut and allowed to dry at room temperature
onto Superfrost positively charged microscopy slides (Fisher Scientific, Pittsburgh, P A)
followed by 5-minute fixation in 0.5% glutaraldehyde at room temperature and a 5-
minute rinse in PBS prior to staining. Whole embryos and embryo sections were stained
for f)-galactosidase activity in X-gal substrate solution (see section 4.2) for 2 hours to
overnight at room temperature depending on embryo size. Histological staining for
cartilage was performed using safranine-O with iron hematoxylin and fast green
counterstains. alkaline phosphatase activity was localized in tissue sections by exposing
frozen and fixed sections to a solution containing 0.5 mg/ml Napthol as MX Phosphate
(disodium salt), 1 mg/ml Fast Red salt, and 2.8% N N dimethyl formamide in 0. 1 M Tris
maleate buffer, pH 8.4 for 15 minutes at 37 C in the dark. All chemicals were obtained
from Sigma Chemical, Madison, WI except where indicated.
RNA Analysis
RNA was isolated from whole embryos using Trizol reagent (In Vitrogen, Carlsbad, CA)
according to the manufacturer s protocol. RT-PCR analysis was caried out using 5 /-g of
total RNA in a reverse transcription reaction with the Superscript reverse transcriptase
(InVitrogen) and oligonucleotide-dT primers for messenger RNA. Twenty five percent
of the resultant cDNA product was then subjected to 30 cycles of polymerase chain
reaction (PCR) using primers specific for the Type II Runx2 isoform or for GAPDH.
Twenty five percent of the resulting PCR product was electrophoresed in a 1 % agarose
gel, transferred onto a Hybond N+ (Amersham Pharmacia, Piscataway, NJ) nylon
membrane and hybridized to p end labeled oligonucleotidenucleotide probe
corresponding to the original PCR primer followed by exposure to X-ray fim.
RESULTS
The bone related Runx2 gene is highly expressed prior to skeletal formation in mouse
embryos.
To understand utilization of the PI promoter in its native locus in vivo we examined the
expression of PI specific mRNAs throughout mouse embryonic development using RT-
PCR analysis. We find that in whole embryos, these transcripts can be detected as early
as 11.5 dpc with a peak in expression at 12.5dpc, followed by a progressive decrease
between 13.5 dpc and birth (at least 10 fold) (Figure 2. A). Interestingly, the peak of
Runx2 expression in the whole embryo occurs at a very early stage of chondrogenesis
prior to the onset of osteogenesis (around 14.5 dpc). The apparent decrease in Runx2
transcript levels during development may be attributable to the lower representation of
skeletal lineage cells in older embryos. We therefore isolated RNA from the heads of
embryos between 15.5 dpc and birth to enrich the RNA pool with osseous tissue and
minimize the contribution of soft or non-osseous tissue. RT-PCR results show that the
expression of PI related mRAs increases as the embryos approach birth, with maximal
expression in the newborn animal (Figure 2. 1- B). These results indicate a transient
upregulation of Runx2 expression during chondrogenesis, and at later stages of bone
formation an additional increase in expression that reflects the requirement for Runx2 in
osteoblast maturation and mineralization.
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Figure 2. 1: RT -PCR analysis of the expression of the endogenous
Runx2 Type II isoform derived from the P1 promoter demonstrates
that in whole embryo extracts, expression peaks at E 12.5 in the
developing embryo (A). When examining Runx2 Type II in osseous
tissues, such as the skull, and increase in expression is observed
as mature bone is formed after birth (B).
To investigate the spatial and temporal expression patterns of the 
Runx2 PI promoter 
vivo we designed a transgenic construct in which a 3 kb promoter region 5' of the
transcription initiation site regulates expression of the 
LacZ reporter gene (Figure 2. A).
The activity of the Runx2 promoter transgene was initially assessed by transient
transfection of Ros 17/2.8 osteosarcoma cells. These cells exhibit significant transgene
activity in comparison to cells transfected with a highly expressing CMV driven 
LacZ
reporter construct (Figure 2. B). Several transgenic founder mice were generated
identified by Southern blot analysis (Figure 2. C) and bred to produce distinct
transgenic lines. Based on results obtained from RT-PCR analysis of Runx2 expression
in the whole embryo , we analyzed promoter activity in vivo prior to the induction of the
endogenous gene at 11.5 dpc and throughout development
The Runx2 promoter is active in mesenchymal condensations at early embryonic stages
prior to sclerotome formation.
To monitor expression of the 3 kb promoter during skeletal development, we analyzed
two distinct lines of transgenic mice at various stages during embryogenesis. These two
lines have similar expression patterns (Figure 2.3-E and F), and there is no background
staining in wild type littermates (Figure 2. G). Transgene expression is detected shortly
after the embryonic turning event at 8.5 dpc (not shown) in the most caudal somites that
begin to give rise to sclerotome around 9.5 dpc (Figure 2. A). Promoter activity
continues in the developing sclerotome until 11.5 dpc (Figure 2.3-B). At 12.5 dpc, f)-gal
expression is located solely in the mesenchyme of the sclerotomes that are destined to
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Figure 2: The 3kb Runx2 P1 transgene (A) exhibits robust
promoter activity after transient transfection ' into Ros 17/2.
osteosarcoma cells as evidenced by X-gal staining (B). This
transgene was then introduced into fertilzed mus musculus
oocytes by pronuclear injection, resulting in the generation of three
expressing founder lines identified by Southern blotting using the
probe pictured in 2. A (C).
Figure 3: Examination of Runx2 P1-LacZ expression throughout
embryogenesis by X-gal staining at E9. E12.5 (A- D) shows -gal
activity in the developing somites. Transgene activity persists in the
developing embryo and is reproducible in two independent mouse
lines (E, &H). Wildtype littermates mice exhibit no background X-
gal staining (G).
give rise to the cartilage and bones of the axial skeleton (Figure 2.3-C; 2.
cryosection). These results indicate that the 3 kb Runx2 promoter contains regulatory
elements that control Runx2 expression in early mesenchymal cells that wil form the
vertebrae and ribs.
The Runx2 promoter supports expression in cells with chondrogenic potential during
development of the axial skeleton.
We examined Runx2 promoter activity in whole embryos (Figure 2.4 , A-C) and in
cryosections (Figure 2.4 , D-I) when mesenchymal condensations of the sclerotome begin
to migrate in a ventromedial fashion to form the cartilage anlagen of the ribs. At 13.
dpc we find intense f)-gal activity at the tip of the migrating rib (Figure 2.4, A-C).
Histological analysis shows that cells expressing f)-gal have not yet produced significant
carilaginous extracellular matrix, reflected by an absence of safranine-O staining (Figure
2.4 , F and G, arrows). This finding reveals that activity of the Runx2 promoter continues
during the differentiation of mesenchymal cells in the anatomical region that wil become
the cartilage of the developing rib. Thus, the promoter is highly active in committed
chondroprogenitor cells.
At 13.5 dpc cells of the sclerotome are also beginning to segregate along the vertebral
column to form the future vertebral bodies (Figure 2.4, H and I, arrows) and
intervertebral discs (Figure 2.4 H and I , arowheads). In this region of the embryo, cells
positive for transgene expression are present in areas that are destined to become
Figure 4: The Runx2 P1 promoter is expressed in pre-
cartilaginous mesenchymal condensations of the axial skeleton.
Whole-mount X-gal staining of E 13.5 mice followed by soft tissue
clarification in 2% KOH reveals strong transgene activity in the
ventromedially migrating cells of the developing rib (A-C).
Cryosections of E13. transgenic embryos stained with X-gal
(E, I) or Safranin-O (D, H) reveal transgene activity in the
caudal, pre-cartilaginous (Safranin-O negative) sclerotome (D-G).
Midsaggital sections of the developing vertebral column reveals
promoter activity in mesenchymal cells destined to form
intervertebral discs (H&I, arrowheads). Condensations destined to
form vertebral bodies exhibit weak Safrnin-O staining at this time
(G, , arrows).
intervertebral discs (Figure 2.4- , arrowheads). Thus, the regions that wil form ossified
vertebrae via endochondral bone formation do not express the 3 kb 
Runx2 transgene.
Taken together our findings reveal that the 3 kb promoter is active in pre-chondrogenic
cells of the intervertebral discs and ribs , and that promoter activity is absent from
chondrocytes, which form the template for future bone tissue of the vertebral body. 
conclude that Runx2 promoter activity demarcates a segmentation event involved in
formation of the axial skeleton.
The kb Runx2 promoter transgene is expressed in mature, but not hypertrophic
chondrocytes during later stages of embryonic development
Based on prior observations in 13.5 dpc animals, we examined promoter activity during
the progressive maturation of chondrocytes in relation to endochondral bone formation.
At 15.5 dpc, the cartilaginous anlagen of the skeleton are well established, and
ossification centers appear in the ribs, long bones, and flat bones of the skull. Para-
sagittal sectioning of 15.5 dpc embryos reveals strong transgene activity in the ribs but a
complete lack of activity in the alkaline phosphatase positive humerus and developing
parietal bone of the skull (Figure 2. , A-C). This finding demonstrates that the 3 kb
promoter is expressed exclusively in the axial skeleton, and not in the appendicular
skeleton or in bones, which undergo intramembranous ossification.
Upon closer examination of cells expressing the trans gene within the rib, it is evident that
the mature chondrocytes of the rib (Figure 2. D, arrow, marked by intense safranine-
staining) exhbit f)-galactosidase activity (Figure 2. , arrow), but this activity decreases
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Figure 2.5: The Runx2 P1 transgene is active in proliferating, but
not hypertrophic chondrocytes of the axial skeleton. Cryosections
of E15.5 embryos stained with Safranin-O (A, G), X-gal (B, H),
or Alkaline Phosphatase (C, I) clearly show transgene activity in
the cartilaginous ribs (B, arrowhead) and a lack of activity in the
cartiaginous humerus (B , arrow). Longitudinal sections of E15.
ribs (D-F) exhibit transgene activity in developing chondrocytes
(arrows), but no activity in hypertrophic chondrocytes
(arrowheads). Midsagittal sections (G-I) of the developing
vertebral bodies reveal transgene activity around the developing
intravertebral discs (arrows) and an absence of activity in the
alkaline phosphatase-positive developing vertebral bodies
(arrowheads).
towards the zone of hypertrophic carilage (Figure 2. , D & E, arowhead, marked by a
decrease in safranine-O and X-gal staining). No f)-gal activity was detected in
hypertrophic chondrocytes producing a mineralized matrix (Figure 2.5, E and F , reflected
by AP staining). Additionally, we observe that the cells of the perichondriumperiosteum
of the rib, which have both chondrogenic and osteogenic potential, express the transgene
(Figure 2. E). These results demonstrate that activity of the 3 kb Runx2 promoter is
reduced during the maturation of chondrocytes.
Similar to our observations in the ribs, cells forming the vertebral bodies of the
developing vertebral colum begin to express alkaline phosphatase (Figure 2. , arow),
which indicates the presence of hypertrophic chondrocytes at 15.5 dpc in a region that
wil become ossified tissue (Figure 2. G and I). Here, regions exhibiting f)-gal activity
and alkaline phosphatase staining are mutually exclusive (Figure 2. H and I). At the
time of birth, transgene activity is retained in the periosteumperichondrium and carilage
of the axial skeleton (Figure 2. A and B). These results indicate that the initial 3 kb
segment of the Runx2 gene promoter confers expression to a subset of chondrocytic
lineage cells , implying that this promoter is responsive to signals transduced by distinct
spatio-temporal regulatory pathways in cells ofthis lineage.
The Runx2 PI promoter is active in the testes of adult transgenic animals.
Post-natal transgenic mice were examined for expression of the transgene at weaning (3-
weeks) and at 6 weeks of age by dissection and staining of individual tissues with X-gal.
Figure 6: The Runx2 P1 promoter is active in chondrocytes of
, newborn transgenic mice. The transgene is highly expressed in the
cartilaginous portion of the ribs (A, arrowhead) but is silenced in the
osseous portion of the rib (A, arrow). (8) Transverse section
through the cartilaginous portion of the rib cage. Arrowhead
indicates area corresponding to the arrowhead in 2.
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Figure 2.7: Transgene activity is observed in the testes of 6-week
old transgenic mice (A), but not in wildtype controls (B). Histological
sections of the testes demonstrate that the Runx2 P1 promoter
activity is localized to cells lining the seminiferous tubules within the
testes.
We examined a broad spectrum of tissues including skeletal tissue (bone , cartilage, and
muscle), major organs (liver, kidneys, lungs, heart, skin, and intestine), lymphoid tissues
(thymus and spleen), and testes for transgene expression. Of all these tissues , expression
was detectable only in the testes, which strongly expressed the transgene in the
seminiferous tubules (Figure 2. , A-D). This finding is consistent with a previous report
which identified transcripts of the bone related Runx2 isoform in testis (Ogawa et al.
2000). Our results also indicate that the 3 kb promoter carries insufficient regulatory
information for activity in mineralized tissue (hypertophic carilage and bone) and in the
matue chondrocytes of adult animals. Taken together, our data demonstrate that spatio-
temporal activity of the 3 kb Runx2 promoter supports early developmental expression of
the endogenous Runx2 gene.
DISCUSSION
In this study we examined the contrbutions of the bone related Runx2 promoter to spatio-
temporal regulation of expression using a PI 3 kb-LacZ transgenic mouse model. We find
the Runx2 promoter is highly active at early stages of embryogenesis. Increasing f)-gal
activity was observed in the somites located in the caudal portion of the developing
embryo from 9.5 to 12.5 dpc, consistent with the observation that endogenous bone
related Runx2 transcripts reach maximal levels at 12.5 dpc in whole embryo preparations.
At 13. 5 dpc, LacZ expressing cells migrate ventromedially to form the cartilaginous
template of the ribs and vertebral column. From 15.5 dpc until the time of birth, the
promoter continues to be active in pre-chondrocytes and mature chondrocytes, and
notably, expression is restricted to the axial skeleton. Taken together, these findings
demonstrate a tissue-restricted expression pattern of the bone related 
Runx2 PI promoter
in mesenchymal populations of chondrocytic progenitor cells, and in early chondrocytes
of the axial skeleton. We conclude that the 3 kb Runx2 promoter is responsive to
developmental cues that establish the segmentation pattern of the ribs and vertebrae.
The role of Runx2 in bone formation and maturation has been well established through
both in vitro and in vivo studies (Banerjee et al. 1997; Ducy et al. 1997; Komori et al.
1997; Mundlos et al. 1997; Otto et al. 1997). In situ hybridization has demonstrated the
presence of bone related Runx2 transcripts in osteoblasts and hypertrophic chondrocytes
of the growth plate (Kim et al. 1999; Enomoto et al. 2000). In vitro model systems of
osteoblast differentiation have clearly defined the role of the bone related isoform 
Runx2 in commitment of cells to the osteoblast lineage, as well as in the induction of
genes associated with mature osteoblast activity (Freytag et al. 1994; Xiao et al. 1999).
Indeed, our results show that Runx2 is dramatically upregulated in ossified tissue at the
time of birth. Previous studies have shown that the bone related isoform of Runx2 is
upregulated in response to the BMP signaling pathway (Enomoto et al. 2000; BaneIjee et
al. 2001) and that BMP signaling is involved in multiple stages of chondrogenesis
(Murtaugh et al. 1999; Pizette and Niswander 2000; Murtaugh et al. 2001). However, the
chondrocyte related promoter activity we observe is unresponsive to BMP/TGF-f)
signaling (unpublished observations, our laboratories). Our findings indicate that bone
specific gene regulatory sequences responsible for controlling 
Runx2 expression in
calcified tissue are located beyond the 3 kb segment used in this study.
Our studies clearly show robust expression of the Runx2 promoter in relation to
chondrogenesis. We observe promoter activity in prechondrocytic mesenchymal
condensations and in the developing chondrocytes of the axial skeleton, but not in the
appendicular limbs. Several groups have identified Runx2 transcripts in pre-
chondrocytic mesenchyme, as well as in both hypertrophic and pre-hypertrophic
chondrocytes of vertebrae and limb bones (Ducy et al. 1997; Inada et al. 1999; Kim et al.
1999; Enomoto et al. 2000). Thus, our results show that the 3 kb Runx2 promoter
contains regulatory information for activation in a subset of cartilaginous tissues
expressing the endogenous gene.
This study represents the first data on developmental expression of the Runx2 
promoter in vivo using a transgenic model. Previous studies reported the combined
activity ofthe upstream bone related (PI) and downstream (P2) Runx2 promoters (Otto et
al. 1997). This group inserted the LacZ gene into Runx2 exon 2 by homologous
recombination, thereby creating a null allele and a reporter that monitors the activity of
both Runx2 PI and P2 promoters. These mice exhibit LacZ activity in the developing
ribs of 12.5 dpc embryos with a staining pattern consistent with the one shown in this
report. In addition, the authors show f)-gal activity in the mesenchyme and periosteum of
the developing radius and ulna. Thus , in comparison to the f)-gal activity resulting from
activation of both Runx2 promoters, the bone related Runx2 PI promoter used in our
studies is active in similar cell types but is limited to the mesenchyme and developing
cartilage of the axial skeleton. The expression profie observed by Otto et al. in the
appendicular skeleton may be derived from activity of the P2 promoter as well as the
presence of additional elements that regulate the PI promoter.
The expression pattern of the Runx2 transgene is strikingly similar to those of the
transcription factors Paxl/Pax9 and Nkx3. , which are involved, in early stages of
development of the axial skeleton (Tribioli et al. 1997; Tribioli and Lufkin 1997;
Furuoto et al. 1999; Lettice et al. 1999; Peters et al. 1999; Tribioli and Lufkin 1999).
Null mutations in these genes cause severe defects in development of the axial skeleton
due to improper sclerotome formation and differentiation. Tribioli and Lufkin (Tribioli
and Lufkin 1999) demonstrated that in Nkx3 
/- 
mice there is a downregulation of the
bone related Runx2 isoform only in the axial skeleton and not in the limbs or other areas
known to coexpress Nkx3.2 and Runx2. These observations suggest that induction of the
Runx2 promoter contributes to early stages of axial  skele n development.
Formation and differentiation of the sclerotome is a process initiated by the Sonic
Hedgehog (Shh) signaling molecule, which originates from the notochord. Shh
expression is coincidental with the activation of both Nkx3.2 and Pax 1 in the
presclerotomal somite (Johnson et al. 1994; Borycki et al. 1998). Interestingly,
endogenous Runx2 promoter activity has also been observed in the notochord at the onset
of chondrogenesis (Otto et al. 1997). Therefore, the expression of the bone related
Runx2 promoter in developing somites and sclerotome might reflect the convergence of
multiple signaling pathways.
Our data support the concept that Runx2 functions in the somite and sclerotome prior to
and during chondrogenesis. Thus , the Runx2 PI promoter used in this study provides a
basis for exploring the complexities of Runx2 in regulating initial stages of
chondrogenesis and segmentation of the axial skeleton.
Chapter 3:
Nkx3. 2 Mediated Repression of Runx2 Promotes
Chondrogenic Differentiation
ABSTRACT
Runx2, a transcription factor known to be essential for osteoblast maturation and
skeletogenesis, is also expressed in pre-carilaginous mesenchymal condensations in the
developing embryo. It is therefore necessar to understand the control and consequential
regulatory activity of the Runx2 gene within the context of chondrogenic differentiation
of a mesenchymal progenitor cell. We identify the homeodomain protein Nkx3.2 as a
potent sequence-specific repressor of the Runx2 promoter that acts through a regulatory
element O. lkb upstream (rom the site of transcriptional initiation. The biological
significance of this repression is established by utilizing BMP- induced chondrogenic
differentiation of pluripotent C3HI0Tl/2 cells as a model for the initial events of
mesenchymal chondrogenesis. We demonstrate that induction of the chondrogenic
phenotype and endogenous Nkx3.2 expression is accompanied by a repression of Runx2
gene activity. Bypassing Runx2 repression by adenoviral-mediated introduction of
Runx2 into C3HI0Tl/2 cells can prevent the induction of chondrogenesis, but cannot
reverse the chondrogenic phenotype once it has been initiated, as evidenced by Sox9 and
collagen Type 2 expression and extracellular matrix deposition. Our results demonstrate
that Run2 is a direct transcriptional target ofNkx3. , and that repression of Runx2 at the
onset of chondrogenesis is a prerequisite for the activation of a chondrocyte-specific
program of gene expression. We postulate that Runx2 is a critical link in BMP-
mediated initiation of mesenchymal chondrogenesis that results in activation of Sox9 at
least in part through the Nkx3.2-dependent repression of Runx2.
INTRODUCTION
During mammalian embryogenesis, the axial skeleton is initially formed as a
carilaginous template prior to conversion into mineralized bone through the coordinated
actions of osteoclasts and osteoblasts. The mesenchymal progenitor cells responsible for
cartilage formation aggregate around the notochord and are induced to proliferate and
subsequently to differentiate in response to the secreted signaling molecules Sonic
Hedgehog (Shh) and BMP-2 (Johnson et al. 1994; Fan et al. 1995; Marcelle et al. 1997;
Murtaugh et al. 1999). The sequential and cooperative action of these molecules results in
the induction of the pro-chondrogenic NK-related homeodomain protein Nkx3.2 in
mesenchymal progenitor cells. Nkx3.2 mediates transcriptional repression of target
genes through its interactions with BMP-responsive SMAD proteins and histone
deacetylase HDACI (Kim and Lassar 2003). Activation of Nkx3.2 is required for and
closely followed by activation of the master chondrogenic transcriptional regulator Sox9.
The activation of Sox9 through Nkx3.2 ultimately leads to activation of chondrocyte
phenotypic genes , including type II collagen and aggrecan and formation of a
cartilaginous extracellular matrix (Murtaugh et al. 1999; Murtaugh et al. 2001). The
importance of Nkx3.2 in this process is evident from Nkx3.2 null mice, in which
mesenchymal progenitor cells of the sclerotome fail to differentiate resulting in
malformation or absence of axial  ske et l elements and perinatal lethality (Lettice et al.
1999; Tribioli and Lufkin 1999; Akazawa et al. 2000).
Recent findings in our laboratory and others have demonstrated that pre-chondrogenic
mesenchymal progenitor cells exhibit Runx2 gene activity as early as 9.5 days post
coitum, 3 days prior to overt chondrogenesis in the murine embryo (Ducy et al. 1997;
Otto et al. 1997; Lengner et al. 2002; Yamashiro et al. 2002). The Runx family of DNA-
binding transcription factors governs cell fate determination in a variety of tissues. Runx
factors are essential for hematopoiesis, skeletal development, and development of the
digestive and nervous systems (North et al. 1999; Guo et al. 2002; Inoue et al. 2002;
Levanon et al. 2002; Li et al. 2002). Runx2 is indispensable for the differentiation of the
bone-forming osteoblast, and Runx target genes in this cell lineage have been well
characterized (Banerj ee et al. 1997; Ducy et al. 1997; Komori et al. 1997; Otto et al.
1997; Choi et al. 2001; Lian et al. 2004). The observation that the Runx2 gene is active
in progenitor cells that are destined to undergo chondrogenesis rather than osteogenesis
necessitates determining whether Runx2 plays a role in BMP-2 induced chondrogenic
differentiation of mesenchymal progenitor cells in addition to the well-characterized
function of Runx2 in promoting the osteogenic differentiation of osteoblast precursors
later during skeletogenesis.
In this study, we identify the Runx2 gene as a target of Nkx3.2-mediated transcriptional
repression and demonstrate that Run2 is a critical link in the BMP-2 induced pathway of
chondrogenesis. We show that Nkx3.2 represses Runx2 activity through an interaction
with a regulatory element in the Runx2 promoter. Furher, our results suggest that at the
onset of BMP-2 induced chondrogenesis of C3HI0Tl/2 mesenchymal progenitor cells
an increase in Nkx3. 2 activity suppresses Runx2 gene expression. We demonstrate that
bypassing the observed suppression of Runx2 at the onset of chondrogenesis inhibits
chondrocytic differentiation. Our findings establish that Runx2 is a critical modulator of
the commitment of mesenchymal progenitor cells to the chondrogenic lineage.
MATERIALS AND METHODS
Cell Culture and Trans;ent Transfect;on
C3HI0T1I2 and NIH3T3 cells were maintained in Dulbecco s Modified Medium
(DMEM , Gibco) supplemented with 10% fetal bovine serum (FBS , Atlanta Biologicals
GA). MC3T3 cells were maintained in a-MEM media supplemented with 10% FBS.
ROSI7/2.8 cells were maintained in F12 media supplemented with 5% FBS. Transient
transfections were performed in 6-well plates at 70% confluence using 5ul of FuGENE6
transfection reagent (Roche, Indianapolis, IN) and 4 fAg total DNA per well in accordance
with the manufacturers protocol. For Nkx3.2 expression, 100 ng of an Nkx3.2 expression
vector in a PCS2 plasmid backbone (a kind gift from Dr. Andrew Lassar at Harvard
Medical School) was transfected into each well unless otherwise noted. As a control , 100
ng PCS2 expression vector ( empty vector) was transfected into each well. For Sox9
expression, 100 ng of a Sox9 expression construct was introduced into each well of a 6
well, plate. Sonic hedgehog (Shh, R&D systems , Minneapolis, MN) and BMP2 (a kind
gift from Dr. John Wozney, Wyeth Ayerst, Cambridge , MA) were added exogenously at
concentrations of 200ng/mL and 100ng/mL respectively. To monitor transfection
efficiency, transfections included 0. 5 f-g of a CMV driven LacZ expression vector per
well. For Run2 promoter-reporter assays, transfections included 2 f-g of either a Run2
6 kb promoter-luciferase construct, or an empty PGL3 luciferase construct. All results
were normalized to activity of the PGL3 empty vector (Promega, Madison WI).
Luciferase Reporter Assays
Cells transfected with Runx2 promoter/luciferase reporter constructs were harested 36-
48 hours after transfection and each well was lysed at room temperature for 20 minutes in
the presence of 0.5 mL Reporter Lysis Buffer (RLB, Promega Madison, WI). Firefly
luciferase activity was quantitated in a luminometer using a 12 second read time
immediately after addition of 20 f-l cell lysate to 100 f-l substrate (Promega Luciferase
Assay System). With the exception of Figure 3. , all results were normalized to the
luciferase activity resulting from transfection of the promoterless PGL3 luciferase
constrct (Promega).
Chondrogenic Induction and A den 0 viral Infection of C3HIOTl/2 Cells
Induction of chondrogenesis was carried out by plating C3HI0T1I2 cells (between
passages 19 and 25) in high-density micromass cultures (10 cells in a 10 f-L drop of
media)(Ahrens et al. 1977; Mello and Tuan 1999; Lengner et al. 2004), followed by a
three-hour incubation period in which cells were allowed to adhere. Following adhesion
micromass cultures were fed with F12 media containing 5% fetal bovine serum and 100
ng/mL recombinant hBMP-2 (kindly provided by Dr. John Wozney at Wyeth-Ayerst
MA). For adenoviral transduction experiments, C3HI0Tl/2 cells were infected with
viruses containing either the Run2 cDNA or the f)-galactosidase cDNA as a control at an
MOI of 100. To introduce adenovirally-expressed proteins prior to chondrogenic
induction, C3HI0Tl/2 cells were infected while proliferating in a monolayer at
approximately 80% confluence. At 12 hours after infection, cells were trypsinized and
plated in high-density micromass cultures for chondrogenic differentiation as described
above. Cultures were harested 24 hours after induction of chondrogenesis for analysis
of gene expression. To deliver adenovirally expressed proteins after induction of
chondrogenesis, C3HI0Tl/2 cells were plated in high-density cultures, allowed to
adhere, then infected with viruses containing either the Runx2 cDNA or the f)-
galactosidase cDNA. Immediately after infection, cultures were fed with F12 media
containing 5% fetal bovine serum and 100 ng/mL recombinant hBMP-2. Cultures were
harested 24 hours after the induction of chondrogenesis for analysis of gene expression.
RNA Isolation and Analysis
RNA was isolated from cultures of C3HI0Tl/2 cells using Trizol Reagent (Invitrogen,
Carlsbad CA) according to the manufacturers protocol. After purification, 5 f-g of total
RNA was DNAse treated using a DNA-free RNA column purification kit (Zymo
Research, Orange, CA). RNA (1 f-g) was then reverse transcribed using Oligo-
primers and the SuperScript Strand Synthesis kit (Invitrogen) according to the
manufacturers protocol. Gene expression was assessed by quantitative real-time PCR
(Sox9, Nkx3. , type II collagen, type I collagen, alkaline phosphatase, and Runx2).
Quantitative PCR was performed using either SYBR green 2x master mix (Eurogentec
Belgium) or Fam-conjugated Taqman probes and Taqman 2x Master Mix in the case of
Nkx3.2 and Runx2 (Applied Biosciences, Foster City, CA) and a 2 step cycling protocol
(anneal and elongate at 60 C, denature at 94 C). All data is expressed as arbitrary
expression levels relative to expression of glyceraldehyde- phosphate dehydrogenase
(GAPDH. Specificity of primers was verified by dissociation of amplicons when using
SYBR green as a detector. Primers used for PCR reactions are listed in Table 1.
Electrophoretic Mobility Shift Analysis (EMSA)
Expression constructs containing the Nkx3.2 coding region or the empty PCS2 vector
were subjected to in vitro transcription/translation (IVTT) using the TNT coupled rabbit
reticulocyte lysate system (Promega) and SP6 RNA polymerase (NEB , Beverly MA)
according to the manufacturer s protocol. In vitro synthesis of recombinant Nkx3.2 was
verified by Western blotting against the HA tag present in the PCS2 vector (data not
shown). Wild type and mutant oligonucIeotidenucIeotides containing the Nkx3.
consensus site derived from the Runx2 PI promoter was end labeled by incubating 10
fAM of the sense strand of each oligonucleotide with 50 fACi of y_
32 -A TP in the presence
of 10 units polynucleotide kinase (PNK, NEB , MA) for 30 minutes at 37 C. Unlabelled
antisense oligonucleotide (30 fAM) was then added to the reaction followed by boilng the
mixture for 5 minutes. The reaction was then gradually allowed to cool to room
temperature to allow the annealing of sense and antisense strands to occur. Double
stranded oligonucleotides were then purified over a G-25 sephadex column to remove
unincorporated nucleotides. DNA binding assays were performed by incubating 10
fioles of double stranded oligonucleotide with 2 g of nuclear proteins from C3H lOT 112
cells along with or without 0.4 g rabbit poly clonal a-HA antibody (Santa Cruz, Santa
Cru, CA) or a non-specific antibody, a-cMYC (Santa Cru), at room temperatue for 20
minutes. Complexes were visualized after separation on a 16% 40:1 acrylamide:bis-
acrylamide gel in the presence ofO.5X TBE buffer followed by autoradiography.
Western Blotting
For the detection of Nkx3.2, Run2 , and Lamin B proteins, each well of a 6 well plate
was lysed in 400 llysis buffer containing 2% SDS , 10 mM DTT, 10% glycerol , 12%
urea, 10 mM Tris/HCI (pH 7.5), 1 mM PMSF , IX Protease inhibitor cocktail (Roche), 25
M MG 132 proteosome inhibitor, and boiled for 5 minutes. Proteins were then
quantified using Bradford reagent (Pierce, Rockford, IL) and taking spectrophotometric
readings at 590 nm. Concentrations were estimated against a standard curve generated
using BSA.
20 g of total protein was subjected to electrophoresis in a denaturing 10%
polyacrylamide gel containing 10% SDS. Proteins were then transferred onto
Immobilon-P membranes (Millpore, Bilerica, MA) using a semi-dry transfer apparatus.
Membranes were blocked in PBS- Ol % Tween-20 containing 2% nonfat-powdered milk
(Biorad, Hercules, CA). Proteins were detected by incubating with antibodies at a
concentration of 50 ng/mL in blocking solution. Antibodies used in this study are as
follows: Nkx3. , a-HA epitope mouse monoclonal antibody (Santa Cruz, Santa Cruz
CA): Runx2 mouse monoclonal antibody was a generous gift from Drs. Y oshi Ito and
Kosei Ito , National University, Singapore: a-Lamin B mouse monoclonal antibody
(Zymed Laboratories, San Francisco, Ca). Primary antibodies were detected with goat a-
mouse secondary antibody conjugated to HRP. Secondary antibodies were detected
using Western Lightning Chemiluminescence Reagent (Perkin Elmer, Boston, MA).
Chromatin Immunoprecipitation Assays (ChIP)
To cross-link proteins to DNA, C3H1OT1I2 cells were incubated for 10 min at room
temperature in IX PBS (3 ml/plate) containing 1% formaldehyde, 25 !lM MG- 132
(Calbiochem/Sigma), and IX protease inhibitor (Roche Molecular Biochemicals
Indianapolis, IN). A final concentration of 0. 125 M glycine was added to the 1 
formaldehyde-PBS solution for neutralization. Cells were collected in PBS after plates
were washed twice with ice cold PBS. The cells were then lysed in lysis buffer
containing 25 mM HEPES/NaOH (pH 7.9), 1.5 mM MgCI2 , 10 mM KCl , 0. 1% NP- , 1
mM DTT, 25 !lM MG-132 and IX complete protease inhibitor. To isolate the nuclei
cells were homogenized in a Dounce homogenizer followed by centrifugation at 1 100
rpm at 4 C. The pelleted nuclei were resuspended in 300 !ll (300 !ll/100 mm plate)
sonication buffer (50 !lM HEPES/NaOH (pH 7.9), 140 mM NaCl, 1 mM EDTA, 1%
Triton X- I00, 0. 1% Na-deoxycholate , 0. 1% SDS, 25 !lM MG132 , IX complete protease
inhibitor). Samples were sonicated to shear DNA into 0. 6 kb fragments. Cellular
debris was removed by centrifugation at 14 000 rpm for 15 min at 4 C and resulting
chromatin-containing solutions were distributed into multiple 1 ml aliquots that were
used as the staring material of all subsequent steps.
Chromatin aliquots were precIeared with 100 
l of a 25% (v/v) suspension of2 g single
stranded DNA coated protein 
AlG and 1 mg/ml BSA. Samples were used directly for
immunoprecipitation reaction with 2 
g of a-HA epitope or a-Runx2 (M- , Santa Cru
Biotechnology) antibody and normal rabbit/mouse IgG as a control. Chromatin
immunoprecipitation reactions were allowed to proceed for 2-4 h at 4 C on a rotating
wheel. Immune-complexes were mixed with 1 00 l of 25% (v/v) pre-coated protein AlG
agarose suspension followed by incubation for 1 hat 4 C on a rotating wheel. Beads
were collected by brief centrifugation and the immunocomplexes were eluted twice by
adding 150 l of freshly prepared elution buffer (100mM NaHC03, 1 % SDS). After
reversal of crosslinks at 68 C overnight, the eluate was treated with 1 00 g/ml proteinase
K followed by phenol-chloroform extraction and ethanol precipitation using 5 
glycogen as carrier. An aliquot (2- l) of each sample was assayed using quantitative
PCR for the presence of specific DNA fragments using primers in the proximal Runx2
promoter. This region contains both the Nkx3.2 binding motif as well as Runx2
autoregulatory motifs. The primers are: Forward CTC CAG TAA TAG TGC TTG CAA
AAA AT-3' and Reverse GCG AAT GAA GCA TTC ACA CAA- Quantitative real-
time PCR was carried out using 2X SYBR Green mix (Eurogentec, Belgium) and a 2-
stage cycling protocol (60 C annealing and extension, 94 C denaturation, 40 cycles).
Amplicon specificity was verified by analysis of melting temperature. All data was
collected during the linear phase of amplification.
RESULTS
The Runx2 PI Promoter is Highly Active in C3HIOTI/2 Cells and is Suppressed by
Nkx3.
To gain insight into th regulation of the Runx2 gene in a pluripotent mesenchymal
progenitor cell , we transfected a vector containing 600 base pairs of the Runx2 
promoter (Drissi et al. 2000; Drissi et al. 2002b) fused to the luciferase reporter gene into
C3HI0Tl/2 cells. The Runx2 promoter (PI-Luc) was transcriptionally active
(approximately 10 times that of a promoterless luciferase construct, PGL3, Figure 3.
in this cell line, comparable to the PI-Luc activity observed in osteogenic ROSI7/2.
cells which express high levels of Runx2 protein. This observation is consistent with
previous findings that the endogenous Runx2 gene is active in mesenchymal progenitor
cells during development in vivo (Ducy et al. 1997; Otto et al. 1997; Lengner et al. 2002;
Yamashiro et al. 2002).
We next examined the effect of various signaling molecules and transcription factors
known to be critical for mesenchymal chondrogenesis in vivo on the activity of the Runx2
PI promoter, including Sonic Hedgehog (Shh), Bone Morphogenic Protein 2 (BMP2),
Nkx3. , and Sox9. These molecules act sequentially during murine embryogenesis and
are critical at different stages for the expansion and differentiation of mesenchymal
progenitor cells into mature chondrocytes (Figure 3.1-B). Our results demonstrate that
Shh, BMP- , and Sox9 exhibit little to no effect on the activity of the Runx2 promoter. In
contrast, expression of the transcription factor Nkx3.2 in C3HI0Tl/2 cells resulted in a
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Figure 1: The Runx2 P1 promoter is active in mesenchymal cells
and is repressed by Nkx3.2. Transient transfection of a 0.6 kb
Runx2 P1 promoter-Luciferase into C3H10T1J2 mesenchymal
progenitor cells or ROS17/2. osteosarcoma cells (A).
Examination of the effects of several molecules known to act during
mesenchymal chondrogenesis reveals the potent repressive
activity of Nkx3.2 on the Runx2 promoter in C3H10T1/2 cells (8).
Transfection of Nkx3. into C3H10T1/2 cells showing dose-
responsive repression of the Runx2 promoter (C).
ChondmCb:1e
Sox9
dramatic, dose dependent suppression of 
Runx2 promoter activity (Figure 3. C). These
findings indicate that the robust activity of 
Runx2 regulatory regions in mesenchymal
progenitor cells is negatively regulated by Nkx3. , a molecule that acts to promote the
chondrogenic differentiation of these cells.
Nkx3.2 Represses the Runx2 Promoter via Interaction with an Nkx3.2 Consensus
Binding Sequence.
We examined the possibility that the Nkx3.2-mediated repression of the Runx2 promoter
occured through direct interaction ofNkx3.2 with its consensus-binding site, HRAGTG
(H= A, C , or T; R= A or G) (Kim et al. 2003). Indeed, we identified two consensus
binding sites for Nkx3. 2 within the Runx2 PI promoter (at -580 bp and -98 bp from the
Runx2 transcription initiation site) (Figure 3. A). To define the contribution of these
sites to Nkx3.2-mediated repression of the Runx2 promoter, we co-transfected the
Nk3.2 expression construct into C3HI0T1I2 cells along with various deletion constructs
of the Runx2 promoter. Figure 3. A demonstrates that the distal Nkx3.2 binding site is
dispensable for repression. However, the - 108 bp Runx2 promoter construct stil exhibits
repression in response to Nkx3. , and removal of this site (-92 bp deletion) results in a
loss of repression, as well as an abrogation of basal promoter activity. When the data is
examined as fold repression mediated by Nkx3.2 upon the deletion constructs, it becomes
evident that an additional promoter region between -458 bp and -351 bp may be playing
a contributing role (Figure 3.2-B). Because there is no acceptable Nkx3.2 consensus
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Figure 3.2: Localizing the repressive effects of Nkx3.2 on the
Runx2 P1 promoter. Co-transfection of Nkx3.2 along with various
deletion constru.cts into C3H10T1/2 cells (A). When data from 3.
A is plotted as fold repression, two repressive domains are
revealed between 351/-458 and -92/-108 (8). The latter region
contains an Nkx3.2 consensus site illulstrated in 3.
binding sequence in the -458/-351 region, this effect may occur independently ofNkx3.
DNA binding.
To validate the interaction between Nkx3.2 and its consensus-binding site at -98 bp in
the Runx2 promoter, electrophoretic mobility shift assays (EMSAs) were performed
using a 24 bp oligonucleotide containing the Nkx3.2 site (Figure 3.3-A). This site lies
downstream of a purine rich region of the promoter in a highly conserved area that
contains binding sequences for a number of transcriptional regulators including HLH
ATF , Vitamin D , as well as Run2 itself. Nkx3.2 binds to this site in a sequence specific
maner as mutation of this site completely abrogates binding activity (Figure 3.3-
compare WT to MT). The specificity of this complex was confirmed using supershift
analysis of the Nkx3.2 interaction with the wild type oligonucleotide. Incubation of the
radiolabelled wild type oligonucleotide results in the formation of a specific protein-DNA
complex only in the presence ofNkx3.2 expression vector (Figure 3. C). The addition of
mouse polyclonal a-HA antibody completely supershifts this complex. To further
confirm that Nkx3.2 is occupying this site in the native promoter, CHiP assays were
performed 24 hours after transfection of Nkx3.2 into C3HI0T1I2 cells. Using antibodies
against endogenous Run2 or HA-tagged Nkx3. , we were able to immunoprecipitate the
Runx2 promoter usmg an a-HA antibody, but not using an a-Runx2 or non-specific
(IgG) antibody, demonstrating that Nkx3.2 is indeed occupying the Runx2 promoter
(Figure 3. D). These results demonstrate that the Nkx3.2 transcription factor interacts
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Figure 3.3: Nkx3.2 interacts with a regulatory motif in the Runx2
promoter. The Runx2 promoter contains an Nkx3.2 consensus
binding site 100bp upstream of the transcriptional start site (A).
This sequence was used to create wildtype or mutated
oligonucieotides for electrophoretic mobilty shift ' assays (EMSA).
EMSA demonstrates that Nkx3.2 can bind the wildtype, but not
mutant oligonucleotides (B). The specificity of the observed
protein-DNA interaction was verified by supershift assay using an
anti-HA antibody against the tagged Nkx3.2 protein (C). Chromatin
immunoprecipitation (CHiP) assay in C3H10T1/2 cells transfected
with HA-tagged Nkx3.2 confirms the physical interaction between
Nkx3.2 and the endogenous Runx2 promoter.
with a functional consensus-binding site in the Runx2 PI promoter approximately 100 bp
upstream from the site of initiation of transcription.
The Proximal Nkx3.2 Binding Site in the Runx2 Promoter is Required for Maximal
Repressive Effects of Nkx3.
To determine whether the proximal Nkx3.2 binding site is responsible for mediating the
observed repression of the Runx2 promoter in the presence of Nkx3 . , we introduced the
mutation used for EMSA analysis into both the -600 bp and the - 108 bp Runx2 promoter
constructs. Mutation of this site in the -600 bp promoter resulted in a significant
abrogation of the Nkx3. 2-mediated repression of the -600 bp Runx2 promoter (Figure
3.4- , from 5 to 2 fold). The persistence of repression of the mutated -600 bp promoter in
the presence ofNkx3.2 may be due the Nkx3.2-responsive region between -458 bp and
351 bp observed in Figure 3.2-B. To minimize the effects of other potential promoter
regions through which Nkx3.2 may act, we introduced the mutation of the Nkx3.
binding sequence into the 108 bp Runx2 promoter construct (Figure 3.4-B). While this
construct has less basal promoter activity than the 600bp construct (see Figure 3. A),
Nkx3.2 stil exhibits strong repressive activity upon this promoter fragment (Figure 3.4-
B). Mutation of the Nkx3.2 binding site in this context abolishes Nkx3.2-mediated
repression of the Runx2 promoter confirming that Nkx3.2 is exerting repressive effects
through this site.
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Figure 4: Introduction of an Nkx3.2 binding-incompetent
mutation of the Nkx3.2 consensus site in the Runx2 promoter
abrogates Nkx3.2-mediated repression. Introduction of the
mutation identified in figure 3.3 into the O.6kb P1-Luc construct
results in a partial loss of promoter activity (A). When this mutation
is introduced into the 108bp P1-Luc construct, Nkx3.2 repressive
activity is abolished (B). Whole cell Iysates of C3H10T1/2 cells
transfected with either HA-Nkx3.2 & CMV-EGFP or vector (PCS-
& CMV-EGFP were FACs sorted to isolate GFP positive cells,
followed by protein extraction and western blotting against the HA
tag and endogenous Runx2 protein demonstrating an Nkx3.
induced reduction of Runx2 protein levels (C).
We next addressed whether the observed Nkx3. 2 mediated-repression of the Runx2
promoter affects physiologic Runx2 levels in C3H 1 OTI/2 cells. These cells were
transfected with the Nkx3.2 expression vector and endogenous Runx2 protein levels were
examined. Expression ofNkx3.2 was verified by western blotting against the HA epitope
tag fused to the Nkx3.2 protein (Figure 3.4-C). In the absence of Nkx3. , Runx2 is
strongly expressed in C3HI0T1I2 cells. Upon forced expression if Nkx3. , we find a
34% apparent reduction in Runx2 protein, which represents greater than a 75% loss of
total Runx2 in transfected cells (when accounting a 40% transfection efficiency). Taken
together, these results demonstrate that Nkx3. 2 suppresses the activity of the Runx2
promoter in pluripotent mesenchymal progenitor cells through its interaction with a
fuctional Nkx3. 2 binding element in the proximal Runx2 promoter.
Nkx3.2-mediated Repression of Runx2 is Abrogated in Cells Committed to the Osseous
Lineage.
To gain insight into the biological significance of Nkx3. 2 repression of the Runx2 gene
we asked whether the observed repression was cell type specific. We found that Nkx3.
mediated repression of the Runx2 promoter was much greater in undifferentiated
mesenchymal cells (C3HIOTl/2 , NIH3T3) in comparison to cells already committed to
the osteoblast lineage (MC3T3 , ROSI7/2.8) (Figure 3.5). This phenomenon may reflect
a biological role for Runx2 repression by Nkx3.2 in undifferentiated mesenchyme , as
Runx2 activity in committed osteoblasts is critical for their ability to differentiate and
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Figure 5: Nkx3. mediated repression of the Runx2 promoter is
abrogated in cells committed to the osseous lineage. Co-
transfection of Nkx3.2 and O. 6kb Runx2 P1 Luc constructs into
undifferentiated mesenchymal cells (NIH3T3, C3H10T1/2) or
committed osseous cells (MC3T3, ROS 17/2. 8) showing that the
repressive effects of Nkx3.2 are much greater in uncommitted
mesenchyme.
NIH3T3
these cells may therefore have passed a differentiation checkpoint after which Nkx3.
2 can
no longer exert repressive effects upon the 
Runx2 gene.
Nkx3.2 and Runx2 Genes exhibit Reciprocal Expression Patterns During
Chondrogenic Diferentiation.
To assess the significance of the specificity of Nkx3.2-mediated repression of the Runx2
gene in undifferentiated mesenchymal cells, we examined the expression of patterns of
endogenous Runx2, Nkx3. 2, Sox9 and type collagen genes during chondrogenic
differentiation of C3Hl OTI/2 cells. These cells proliferate as undifferentiated fibroblasts
and, like primary mesenchymal progenitor cells, are capable of differentiating into
several cell types including adipocytes (Zehentner et al. 2000; Chan et al. 2003),
osteoblasts (Spinella-Jaegle et al. 2001; Chan et al. 2003), myoblasts (Singh et al. 2003),
and chondrocytes (Denker et al. 1999; Haas and Tuan 2000), depending on the
environment in which they are cultured. Here C3HI0Tl/2 cells were induced to undergo
chondrogenesis by plating them in high-density micromass cultures in the presence of
BMP2 (Denker et al. 1999).
Gene expression was monitored over a 4-day period after induction of chondrogenesis
(Figure 3.6). Strong induction of Nkx3.2 expression was observed by one day of cultue
and was closely followed by activation of the expression of the chondrogenic
transcriptional regulator Sox9 and of the cartilage-specific extracellular matrix protein
collagen type 2, demonstrating that these cultures have entered the pathway of
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Figure 3.6: Runx2 and Nkx3. exhibit reciprocal expression
patterns during mesenchymal chondrogenesis. C3H10T1/2 cells
were induced to undergo chondrogenic differentiation in response
to high-density culture and BMP-2 treatment. Gene expression
was monitored over a four day time period using quantitative RT-
PCR. Chondrogenic genes Nkx3.2. Sox9 , and collagen type II
are induced 24 hours after induction of chondrogenesis.
Conversely, Runx2 gene expression is suppressed by the 24
hour time point.
chondrocytic differentiation. In contrast, Runx2 expression was strongly repressed by
one day of culture; consistent with our findings that Nkx3.2 activity suppresses
expression of the Runx2 gene. Taken together these findings demonstrate that a loss of
Runx2 gene activity is associated with the transition of the C3HI0Tl/2 mesenchymal
progenitor cell into the chondrogenic lineage.
Runx2 Acts to Prevent Mesenchymal Progenitor Cells from undergoing
Chondrogenesis.
Based on our observations of Runx2 gene expreSSIOn during chondrogenesis of
C3HI0Tl/2 cells, we tested the hypothesis that there is a requirement for Runx2
suppression for induction of chondrogenesis. We therefore introduced exogenous Runx2
into C3HI0Tl/2 cells by adenoviral infection prior to induction of chondrogenesis in
order to circumvent the suppression of Runx2 observed at the onset of chondrogenic
differentiation. Proliferating C3HI0Tl/2 cells were infected with adenovirus containing
either Runx2 cDNA or LacZ cDNA as a control , and gene expression was analyzed 24
hours after the induction of chondrogenesis with BMP2 and high-density culture.
Adenoviral infection maintains high levels of Run2 expression 24 hours after induction
of chondrogenesis in Runx2 infected cells when compared to LacZ infected control
cultures (Figure 3. A). Remarkably, BMP2 treated micromass cultures infected with
Runx2 fail to significantly activate Sox9 or type 2 collagen genes (Figure 3. A) and are
unable to produce significant carilaginous extracellular matrix, as assessed by alcian blue
staining of sulfonated proteoglycans present in carilage (Figure 3. , upper panel).
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Figure 7: Overexpression of Runx2 in C3H10T1/2 cultures
prevents entry into the chondrocytic lineage. Runx2-containing
Adenoviral infection of C3H10T1/2 cells prior to initiation of
chondrogenesis prevents induction of collagen type II , and Sox9,
while only marginally increasing osteogenic markers collagen type I
and alkaline phosphatase (A). Alcian blue and alkaline
phosphatase staining of chondrogenic cultures infected with Ad-
Runx2 or Ad-LacZ reflects the observed changes in gene
expression (B). When Ad-Runx2 is introduced after initiation of
chondrogenesis in C3H 1 OT1/2 cultures, Runx2 is no longer
capable of altering chondrogenic gene expression (C).
Surrisingly, when analyzing expression of Nkx3.2 in these cultures we found that it was
significantly increased in the presence of Runx2, supporting the hypothesis that Nkx3.
acts upstream of Runx2 and suggesting that a feedback loop exists in which the 
Nkx3.
gene becomes induced to suppress Runx2 activity (Figure 3. A). Our results clearly
demonstrate that in an undifferentiated mesenchymal progenitor cell , Runx2 is able to
inhibit chondrogenic differentiation, and Runx2 repression may be a pre-requisite for
entry into the chondrocytic lineage.
Given the role of Runx2 in promoting osteogenesis, we examined whether the inhibition
of chondrogenic differentiation in adenoviral-Runx2 infected C3HlOTI/2 cultures was
associated with increased osteogenesis. We examined adenoviral cultures for expression
of the osteogenic genes alkaline phosphatase (AP) and type I collagen 
and observed that
mRNA levels of these genes were indeed increased in the presence of Runx adenovirus
(Figure 3. A). When examining the activity of the alkaline phosphatase enzyme in these
cultues by colorimetric reaction we observe that AP-positive cells are localized primarily
to cells in monolayer at the edges and top surface of the nodule (Figure 3. B, lower
panel). These observations suggest that while sustained Runx2 activity under pro-
chondrogenic culture conditions prevents the majority of these cells from undergoing
chondrogenesis , it's expression is capable of inducing an osteogenic response in a subset
of these cells.
Interestingly, we find that if Runx2 is introduced by adenoviral infection after the onset
of chondrogenic differentiation it is unable to suppress chondrocyte phenotypic genes
(Figure 3. 7 -C). This phenomenon may reflect the passing of a critical checkpoint during
the chondrogenic differentiation of mesenchymal cells after which the activity of Run2
cannot reverse the differentiation process once the program of chondrogenesis has begun.
Taken together, these findings indicate that suppression of 
Runx2 gene expression by
Nkx3.2 is a requirement for the progression of chondrogenic differentiation of
mesenchymal progenitor cells.
DISCUSSION
In this study we identify the Runx2 gene as a direct target for repression by the NK-
family homeodomain factor Nkx3.2. We establish the biological significance of this
repression by demonstrating that inhibition of Runx2 expression at the onset of BMP-
induced chondrogenesis of C3HI0T1I2 mesenchymal progenitor cells is a pre-requisite
for cartilage formation. While prior studies have shown that osteogenic differentiation of
progenitor cells in response to BMP-2 treatment requires Runx2 activity, our results
demonstrate for the first time that BMP-2 induced chondrogenic differentiation of
mesenchymal progenitor cells requires suppression of Runx2. This finding provides
direct evidence that Runx2 is also a critical regulator of BMP-2 induced chondrogenic
fate determination in pluripotent mesenchymal cells.
, '
We identified Nkx3. 2 as a potential regulator of the Runx2 gene based on the pattern of
Runx2 promoter activity in pre-cartilaginous mesenchymal condensations of the axial
skeleton as early as E9.5 in the murine embryo (Lengner et al. 2002). Cells comprising
the mesenchymal condensations first proliferate, then undergo chondrogenic
differentiation in response to the coordinated and sequential actions of soluble signaling
molecules sonic hedgehog and BMP-2 (Marcelle et al. 1999; Murtaugh et al. 1999;
Murtugh et al. 2001). The expression of the Runx2 gene in these condensations precedes
the activation of Nkx3.2 and overt chondrogenesis. Chondrogenic differentiation of these
cells is dependent upon activation ofNkx3.2 by Shh and BMP- , which ultimately leads
to induction of Sox9 (Murtaugh et al. 1999; Murtaugh et al. 2001; Zeng et al. 2002) .
Runx2 expression is absent from mature chondrocytes: thus the repression of Runx2 by
Nkx3.2 at the onset of chondrogenesis is a key regulatory event. Later during
endochondral bone formation, Runx2 is induced again during the final stages of
hypertrophic cartilage mineralization to promote terminal differentiation prior to turover
of mineralized carilage into bone.
Significantly, we find that the Nkx3.2 regulatory element (CACTT) at -108 bp in the
Runx2 PI promoter is located in a region that is essential for basal transcriptional activity.
This element lies in close proximity to Run and other regulatory sites and marks the 5'
boundary of the minimal promoter region required for transcriptional activity. This
Nkx3.2 site confers potent, dose-dependent transcriptional repression in the presence of
Nkx3.2. Our findings show that Nkx3.2 physically interacts with the Nkx3.2 binding
element within the Runx2 promoter, and that this interaction is required for effective
repression of Runx2 promoter activity. These results make Runx2 the first bona fide
target of Nkx3.2 to be identified to date.
Based on our prior observations of 
Runx2 promoter activity in vivo and our findings in
this study demonstrating that the 
Runx2 gene is a target of Nkx3.2-mediated
transcriptional repression, we investigated the biological significance of 
Runx2 gene
activity in pre-chondrogenic mesenchymal progenitors as they undergo BMP-2 induced
chondrogenesis. Although the mechanisms that support Runx2 gene activity in these
progenitor cells are unown, several lines of evidence suggest that Runx2 is responsive
to sonic hedgehog signaling. In this study we observe a minor (10%) activation of Runx2
promoter activity in response to Shh treatment of C3Hl OT1I2 cells. The lack of a robust
response to Shh may reflect the fact that these cells have endogenously active 
Runx2. 
support of this, other studies have observed an induction of 
Runx2 as a result of Shh
treatment (Takamoto et al. 2003) and have observed that the 
Runx2 gene is active in the
notochord (the source of soluble Shh during embryogenesis) 
in vivo (Otto et al. 1997).
Thus , the Runx2 gene appears to be responsive to signaling pathways that are essential
for early skeletal development.
Later during development of the axial skeleton, BMP-2 acts in concert with Shh to
activate Nkx3.2 and induce carilage formation (Zeng et al. 2002). The sequence 
events is recapitulated in this study using the C3HI0Tl/2 model of mesenchymal
chondrogenesis. Upon BMP-2 treatment and high-density culture, Nkx3.2 is induced and
Runx2 is concomitantly repressed, supporting our findings that Nkx3.2 is an inhibitor of
Runx2 gene expression, and suggesting that the activity of Runx2 must be suppressed
prior to activation of the chondrogenic program of gene expression. This conclusion is
further supported by the finding that adenoviral overexpression of Runx2 prior to
chondrogenesis inhibits induction of Sox9 , collagen type and the chondrogenic
phenotype. The observation that elevating Runx2 levels after induction of
chondrogenesis does not suppress expression of chondrocyte phenotypic genes indicates
that a developmental ' checkpoint' has been passed. Subsequently, the abilty of Runx2 to
maintain an undifferentiated progenitor is lost.
While these findings underscore the importance of Runx2 repression at the onset of
mesenchymal chondrogenesis, the function of Runx2 in undifferentiated mesenchyme
remains unclear. These progenitor cells express Runx2 during proliferative expansion
both in vivo and in vitro. This observation raises the question whether Run2 maintains
an undifferentiated phenotype during expansion of the progenitor population. In this
study, circumvention of Runx2 repression at the onset of BMP-2 induced cartilage
formation efficiently inhibits activation of chondrocyte phenotypic genes and
extracellular matrix deposition. It is therefore possible that these cells either remain
undifferentiated in the presence of exogenous Run2 and BMP-2 or, alternatively become
osteogenic. However, we did not observe induction of the bone phenotypic marker
osteocalcin (not shown) and observed only a minor induction of alkaline phosphatase (an
early osteogenic marker) that was restricted to cells at the periphery and on the surface of
the micromass cultures. While other studies have observed induction of Runx2 and
osteogenic gene expression upon BMP-2 treatment of C3HI0Tl/2 cells in monolayer
cultures, we find that the osteogenic phenotype cannot be induced in high-density
micromass cultures despite the high levels of exogenous Runx2 and BMP-2. These
findings suggest that cell-cell contact in high-density cultures predisposes cells to
undergo chondrogenesis in response to BMP-2 signaling.
Our findings further suggest that a feedback loop may exist in which high levels 
Runx2 positively affect the Nkx3.2 gene in order for Nkx3.2 to repress Runx2 and
thereby promote chondrogenesis. This conclusion is based on the observation that BMP-
2 treated micromass cultures infected with Runx2 adenovirus exhibit increased Nkx3.
expression in comparison to lac- infected controls. These findings are of paricular
interest in light of the observation that the ability of Nkx3.2 to repress Runx2 gene
expression is severely abrogated in committed osteoprogenitor cells , suggesting that
Runx2 may act as a switching mechanism for differentiation induced by BMP signaling.
In an undifferentiated mesenchymal progenitor cell, Runx2 may maintain a pluripotent
state until receipt of a BMP-2 signal. Depending on the microenvironment of the
progenitor cell, BMP-2 can induce Nkx3.2 to suppress Runx2 and promote chondrogenic
differentiation of the pluripotent progenitor (Figure 3.8). Once chondrogenesis has begun
and Sox9 is activated, Runx2 cannot reverse the differentiation process. If the BMP-
signal is osteogenic, the progenitor cell wil further induce Runx2 and activate Osterix
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Figure 8: Model for Runx2 Modul ation of BMP- induced
o ifferentiaion. Previous findings have shown in vivo and in
monolayer cultures of mesenchymal progenitor cells that BMP-
induc,es the osteogenic phenotype via activation of Runx2. Runx2
is necessary for activation of Osterix and other osteoblast
phenotypic genes. BMP2 itself can also lead to Osterix
acc.umulatlon, however this seems occur Independent of
transcriptional activity of the Osterlx gene (dashed arrow)
condensing mesenchyme or high-density micromass cultures,
BMP.2 activity activates NkX3.2 , which in tum suppresses Runx2
transcription. This repression of Runx2 allows for activation of
SOx9 and expression of chondrocyte phenotypic genes. Activation
of NkX3.2 by BMP-2 therefore indirectly leads to SOx9 expression
and chondrogenesis.
another essential pro-osteogenic transcription factor whose activities, along with those of
Runx2 , are responsible for osteoblast formation (Nakashima et al. 2002; Lee et al. 2003;
Ohyama et al. 2004). In this context, the committed pre-osteoblast has passed another
checkpoint' in differentiation where the activity of Nkx3. 2 is no longer competent to
repress Runx2 gene expression and therefore no longer able to promote entry into the
chondrogenic lineage.
In conclusion, we have identified a novel role for Runx2 as a critical component of the
differentiation program that is initiated by activation of the sonic hedgehog and BMP
signaling pathways and ultimately results in the chondrogenic differentiation of
mesenchymal progenitor cells and formation of the cartilaginous template of the
vertebrate skeleton.
Chapter 4:
Primary Mouse Embryonic Fibroblasts: A Model of
Mesenchymal Cartilage Formation
ABSTRACT
Cartilage formation is an intricate process that requires temporal and spatial organization
of regulatory factors in order for a mesenchymal progenitor cell to differentiate through
the distinct stages of chondrogenesis. Gene function during this process has best been
studied by analysis of in vivo cartilage formation in genetically altered mouse models.
Mouse embryonic fibroblasts (MEFs) isolated from such mouse models have been widely
used for the study of growth control and DNA damage response. Here we address the
potential ofMEFs to undergo chondrogenic differentiation. We demonstrate for the first
time that MEFs can enter and complete the program of chondrogenic differentiation 
vivo from undifferentiated progenitor cells to mature, hypertrophic chondrocytes. We
show that chondrogenic differentiation can be induced by cell-cell contact or BMP-
treatment, while in combination, these conditions synergistically enhance chondrocyte
differentiation resulting in the formation of 3-dimensional cartilaginous tissue ex-vivo.
Temporal expression profies of pro-chondrogenic transcription factors Nkx3.2/Nkx3.2
and Sox9 and cartilaginous extracellular matrix proteins collagen type II and X
demonstrate that the in vivo progression of chondrocyte maturation is recapitulated in the
MEF model system. We utilize this model system for analysis of chondrogenesis in
MEFs that are nullizygous for Runx 1 , Runx2 , or both Runx family members. Our
fmdings suggest that these genes play distinct, non-overlapping roles in chondrogenesis.
We find that MEFs lacking Run2 enter into the chondrogenic lineage and form cartilage
tissue ex vivo. These cells, however, fail to mineralize the extracellular matrix and do
not become fully hypertrophic. Runxl null MEFs are able not only to enter the
chondrogenic lineage, but are also capable of achieving hypertrophy 
ex vivo. These cells
form less cartilage than wildtype counterparts, seemingly due to a decreased proliferative
capacity. Further, deletion of both Runx family members does not result in abrogation of
chondrogenic differentiation or the ability of MEFs to activate chondrocyte-specific
genes in response to BMP2 treatment and high-density culture. These results indicate
that Runxl and Run2 play non-redundant roles in mesenchymal chondrogenesis. Our
findings establish the MEF as a powerful tool for the study of gene function during
chondrogenesis. The MEFs capacity for chondrogenic differentiation has further enabled
us to examine the contribution of 
Runx gene fuction during commitment to this lineage.
'-'
INTRODUCTION
Chondrogenic differentiation of mesenchymal cells and the subsequent formation of
cartilaginous tissue are governed by an exquisitely regulated series of events in which
both spatial and temporal regulation of gene activity must be tightly controlled to achieve
the formation of viable tissue. Currently, analysis of chondrocyte differentiation is
limited to in vitro analysis of primar chondrocytes as well as immortalized cell lines and
to in vivo analysis using mouse and rat models. In vitro systems for chondrogenic
differentiation have classically used a combination of BMP-2 treatment and high-density
culture in order to induce chondrogenesis. These culture conditions have proven
effective in both the immortalized C3HI0Tl/2 pluripotent mesenchymal progenitor cell
line (Denker et al. 1999; Carlberg et al. 2001; Nochi et al. 2004) as well as in primar
cultures of bone marow stromal cells (Mackay et al. 1998; Muraglia et al. 2003).
In vivo genetic approaches represent a powerful tool for understanding the spatio-
temporal organization of carilaginous tissue as well as for understading the contribution
of specific genes to the process of chondrogenesis through the use of transgenic and
targeted gene deletions in the mouse (de Crombrugghe et al. 2001; Akiyama et al. 2002).
Chondrocytes, however, do not begin to undergo differentiation in the developing
embryo until the latter half of gestation, making the analysis of chondrogenesis in
embryonic lethal murne knockout models technically challenging. In order to analyze
the contribution of genes whose deletion results in embryonic lethality to the process of
chondrogenesis, we have turned toward the developing mouse embryo for a source of
cells that have chondrogenic potential and can be isolated prior to overt chondrogenesis
during the latter half of gestation. We have identified the mouse embryonic fibroblast
(MEF) as a candidate for such a cell type based on several very appealing properties.
The MEF is a cell isolated from mid- gestation mouse embryos and cultured ex-vivo.
These cells are capable of undergoing a limited number of population doublings before
entering crisis and senescence-like growth arest (Espejel and Blasco 2002; Rossi et al.
2003). Their ease of isolation and the ability to derive these cells from mice harboring
various genetic alterations (both targeted and non-targeted) has made the MEF ideal
model system for studying aspects of cell growth control and functional genetics (Lowe
et al. 1994; Kamijo et al. 1997; Rzonca et al. 2004; Steinman et al. 2004). Since many
murine knockout lines, including those harboring inactive Runx alleles, exhibit
embryonic lethality, the MEF provides an invaluable system for studying cellular
processes in such lines. Few reports however, have utilized the MEF as a tool for the
study of cell differentiation. The ability of the MEF to undergo adipogenic differentiation
ex vivo has been demonstrated by several groups (Alexander et al. 1998; Yun et al. 2002;
Landsberg et al. 2003). Since adipocytes share a common mesenchymal origin with
several other cell types, including osteoblasts and chondrocytes , we set out to develop a
model system of mesenchymal chondrogenesis using the MEF. Here we address the
ability of the MEF to undergo a program of chondrogenic differentiation, thereby
providing a tool that enables the study of a mesenchymal progenitor cell' s entry into and
journey through the chondrogenic pathway as well as identifying a source of cells that
can be expanded significantly for the purpose of tissue generation. In addition , we
examine the ability of MEF cultures lacking either or both 
Runxl and Runx2 genes to
enter and complete the program of chondrogenic differentiation.
Both Runxl and Runx2 genes exhibit distinct spatio-temporal expression patterns durng
chondrogenesis (Drissi et al. 2004; Yamashiro et al. 2004). Based on transgenic and
knock-in animal models it has been shown that the Runx2 gene is active in mesenchymal
progenitor cells in the developing embryo as well as in hypertrophic chondrocytes.
While it's role in matuation of the hypertophic chondrocyte is well understood (Strcker
et al. 2002; Iwamoto et al. 2003; Komori 2003; Zheng et al. 2003; Smits et al. 2004;
Yoshida et al. 2004), the presence of Run2 in pre-chondrocytic mesenchyme is not
understood. Since Runx2 null mice exhibit no apparent defect in the differentiation of
these mesenchymal cells, we hypothesize that Runx 1 may playa role redundant to that of
Runx2 during the proliferation and differentiation of these cells. Runxl null mice die
prior to the migration and differentiation of mesenchymal progenitor cells from
hemorrhage and a block in hematopoesis (Wang et al. 1996; North et al. 2002) making
the study of chondrogenesis in these mice infeasible. Runxl is co-expressed with Runx2
in mesenchymal condensations (Yamashiro et al. 2002; Lian et al. 2003) suggesting that
these family members may play redundant roles in mesenchyme. To address this
possibility we utilize a Runxl conditional allele (Runxl fix/flx) that has been bred onto a
Run2 null allele. We examine the effects of the loss of either one or both of these Runx
factors on chondrogenic differentiation of the mesenchymal mouse embryonic fibroblast.
MATERIALS AND METHODS
MEF Isolation and Culture
MEFs were isolated from mouse embryos derived from C57/B6 mothers between 10 and
12 days of gestation (EI0-EI2). Briefly, each embryo was sheared in an 18-gauge
syringe in the presence of 1 mL 0.25% trypsin/l mM EDT A (Gibco , Carlsbad CA) per
embryo and incubated at 37 C for 15 minutes. Trypsin was inactivated by addition of
DMEM (Gibco) containing 15% FBS (HyClone , South Logan UT) and cells were then
plated in 10 cm culture dishes and allowed to adhere for 24 hours. Non-adherent cells
were then discarded and cells in the adherent fraction are termed MEFs. MEFs were
expanded by passaging pre-confluent cultures at a 1:5 ratio prior to induction of
differentiation. Differentiation experiments were cared out using cells between passage
3 and 5. Animals were treated in accordance with IACUC guidelines.
Runxl null MEFs were generated by crossing Runxl f/f mice (a kind gift from Dr. Nancy
Speck, Dartmouth NH) against one another and harvesting MEFs as stated above
followed by infection with Cre-recombinase containing adenovirus (University of Iowa
Gene Vector Core) or control Lac- containing adenovirus at an MOI of 100. Runx2 null
MEFs were generating by crossing Runx2+/- mice (a kind gift from Dr. Toshihisa
Komori , Japan) against one another and harvesting MEFs. Runxl/Runx2 null MEFs
were generating by crossing Runx 1 f/+ Runx2 +/- mice against one another and harvesting
MEFs as previously stated. Runxl RunxT/- and control MEFs were then infected with
Cre-recombinase containing adenovirus (University of Iowa Gene Vector Core) 
control Lac- containing adenovirus at an MOI of 100.
Chondrogenic Induction
In order to stimulate chondrogenic differentiation, we sought to recapitulate the in vivo
environment of mesenchymal condensations in the embryo using various culture
conditions. Cells were either plated onto 6 well plates in high-density micromass cultues
(1 0 cells in a 10!!L drop of media) (Ahens et al. 1977; Mello and Tuan 1999) or as a
monolayer (10 cells/well) both in the presence or absence of 100 ng/mL recombinant
hBMP-2 (kindly provided by Dr. John Wozney at Wyeth-Ayerst, Cambridge MA).
High-density culture provides cell-cell contact in three dimensions similar to that which
occurs in vivo in condensing mesenchyme prior to induction of chondrogenesis. BMP-
was chosen because it has been shown to be a potent chondrogenic factor for
mesenchymal stem cells in vitro (Denker et al. 1999; Schmitt et al. 2003) and plays an
important role in the chondrogenesis of condensed mesenchyme in vivo (Zeng et al.
2002).
RNA Isolation and Analysis
RNA was isolated at various times during a 12-day culture period using Trizol Reagent
(Invitrogen, Carlsbad CA) according to the manufacturers protocol. After purification, 5
ug of total RNA was DNAse treated using a DNA-free RNA column purification kit
(Zymo Research, Orange , CA). One g of RNA was then reverse transcribed using
Oligo-dT primers and the SuperScript 1 
sl Strand Synthesis kit (Invitrogen) according the
manufacturers protocol. Gene expression was assessed by semi-quantitative (collagen
type II and X, 25 cycles) and quantitative real-time PCR (Sox9, Nkx3.2/Nkx3. , alkaline
phosphatase, osteocalcin, Indian hedgehog). Quantitative PCR was performed using
SYBR green 2x master mix (Eurogentec, Belgium) and a 2 step cycling protocol (anneal
and elongate at 60 , denature at 94 C). Data are expressed as arbitrary expression level
relative to GAPDH expression level. Specificity of primers was verified by dissociation
of amplicons. Primers used for PCR reactions are listed in Table 1. Results are
representative of three or more independent experiments.
Histology
MEF cultues were fixed in 4% paraformaldehyde for 10-15 minutes prior to histological
analysis. Alcian blue staining was performed using 1 % Alcian blue GX8 (Sigma)
solution, pH 8 , overnight. Safranine-O staining was performed using a 0. 1 % Safranine-
solution for 10 minutes at room temperature. Von Kossa stain for mineralized tissue was
performed using a 3% silver nitrate solution and staining for 10 minutes in direct
sunlight. Alkaline phosphatase enzmatic activity was detected by colorimetric reaction
using a 0. 1 M Tris maleate buffer (pH8.4) containing 0.05% Napthol as Mx Phosphate
disodium salt, 2.8% N N dimethyl formamide , and 0. 1 % Fast Red salt. Staining was
carried out at 37 C for 10 minutes (Gold Biotechnology, St Louis, MO) in phosphate
buffered saline (PBS , pH 7.3) at room temperature for 10- 12 hours.
Scanning Electron Microscopy
Cartilage spheroids were fixed by immersion in 2.5% (v/v) glutaraldehyde in 0. 5 M Na
cacodylate-HCl buffer (pH 7.2) for 1 hr at room temperature; the fixed samples were
washed three times in the same buffer. Following the third wash the cells were post
fixed for 1 hr in 1 % osmium tetroxide (w/v) in the same buffer, washed three more times
in the same buffer and left overnight at 4 C in fresh buffer. The next morning the
samples were dehydrated through a graded series of ethanol to 100% and then critical
point dried in liquid C02. The bottoms of the dishes were isolated and affixed to
aluminum SEM stubs using silver conductive paste and sputter coated with Au/Pd
(80/20). The specimens were then examined using an ETEC autoscan scanning electron
microscope at 20 K v accelerating voltage.
RESULTS
BMP2 and High Cell Density are Required/or Entry 0/ Mouse Embryonic Fibroblasts
into the Chondrogenic Lineage
We initially established appropriate culture conditions for induction of chondrogenesis by
MEFs as reflected by several established markers for progression of the chondrocyte
phenotype. Cells were plated to grow either as a monolayer or as a high-density
niicromass culture in the presence or absence of BMP2 (Figure 4. 1). In the absence of
BMP2 , entry of MEFs into the chondrogenic lineage occurred in response to cell-cell
contact in monolayer culture post-confluence, as assessed by the transcriptional activity
of the Nk3.2 gene. Nkx3.2 is the earliest known marker of chondrogenic commitment
in undifferentiated mesenchyme (Lettice et al. 1999) and its activation is a prerequisite
for induction of Sox9, the canonical 'master regulator ' of chondrogenesis whose activity
induces expression of various chondrocyte phenotypic genes, such as collagen type II
(Coil II) (Lefebvre et al. 1998; Bi et al. 1999; Zeng et al. 2002). Nkx3.2 and Sox9
expression was induced in post-confluent monolayer cultures between days 9 and 12
(Figure 4. A); however, this did not translate into significant cartilaginous extracellular
matrix (ECM) production, as evidenced by lack of Coil II expression (Figure 4. C). The
addition of BMP-2 to monolayer cultures resulted in a more rapid induction of Nkx3.
and Sox 9 that lead to a modest induction of CoIl II transcription post-confluence. These
findings indicate that while BMP-2 treatment of monolayer MEF cultures can induce the
chondrogenic program after cells have achieved confluence, the chondrogenesis is
inefficient.
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Figure 4.1: Chondrogenic induction of mouse embryonic fibroblasts (MEFs).
RNA was isolated from MEFs cultured under various conditions and analyzed
for chondrocyte phenotypic gene expression by quantitative RT-PCR at the
indicated times. Monolayer cultures (MO, open symbols) induce pro-
chondrogenic transcription factors Nkx3. 2 and Sox9 in post-confluent cultures
(A). Addition of BMP2 to these cultures results in a more rapid induction of
these genes (MO, solid symbols). Micromass cultures (MM, open symbols)
moderately induce Sox9 and Nkx3.2 in the absence of BMP2 (B). Addition of
BMP2 to these cultures (MM. solid symbols) results in an earlier and more
robust induction of these genes. Type II collagen, an cartilaginous ECM
component and Sox9 target gene, is strongly induced only during micromass
culture in the presence of BMP2 (C). Cartilaginous extracellular matrix is
visualized with alcian bue and safranin-O stains which have an affinity for
negatively charged ECM secreted by chondrocytes (D).
High-density culture (micromass) of MEFs in the absence of BMP-2 resulted in the
induction of Nkx3.2 and Sox9 expression (Figure 4.1-A), and similarly to monolayer
cultures, this activation lead to weak induction of the chondrogenic phenotype observed
by 9 days of culture, as judged by collagen II expression (Figure 4. C). In contrast
addition of BMP-2 to high-density micro mass cultures synergistically activated
expression of the Nkx3.2 and Sox9 genes by 3 days of culture (Figure 4. B). Unlike
BMP-2 treated monolayer cultures or untreated monolayer/micromass cultures, the
Nkx3.2/Sox9 induction in BMP-2 treated micromass cultures resulted in a robust
activation of the Coil II gene. These results demonstrate that cell-cell contact and the
BMP-2 signal cooperate for the transcriptional activation of the chondrocyte-specific
transcription factors Nkx3.2 and Sox9, and their induction synergistically drives robust
chondrogenesis in MEFs, recapitulating the early stages of mesenchymal chondrogenic
differentiation.
We next examined the organization of the extracellular matrix secreted by chondrogenic
MEFs via incorporation of Alcian blue and Safranine- staining for sulfonated
proteoglycans typical of carilage and found that after 6 days of high-density culture
(MM) cartilaginous matrix was only deposited when BMP-2 was added to the culture
medium (Figure 4. 1, D). To further characterize the chondrogenic differentiation of
MEFs and the formation of carilaginous tissue, we performed cell morphology studies
on BMP-2 treated MEFs in micromass culture. Scanning electron microscopy
demonstrates that after 8 days of culture, there is an accumulation of extracellular matrix
Figure 4.2: Scanning electrn microscopy of MEFs. MEFs
cultured at high density in the presence of BMP2 can be seen
secreting proteoglycan fibrils (arrows) as well as collagen sheets
(arrowheads) characteristic of chondrocytes at low (A) and high (8)
magnification .
proteins that are deposited over cells. Individual cells are observed secreting
proteoglycan strands (Figure 4.2, arrows) and collagen fibers (Figure 4. , arowheads).
Thus, chondrogenic induction of MEFs results in the formation of a cartilaginous
.1'
spheroid with tissue-like organization.
Chondrocytic MEF Cultures Undergo Hypertrophy
Having established that MEFs are competent to enter the chondrogenic lineage , we asked
whether these cultures were able to complete the program of chondrocyte maturation by
undergoing cellular hypertrophy, characterized by the expansion of the chondrocytic cell
body, the expression of type X collagen (Coll X), and the induction of alkaline
phosphatase (AP) enzymatic activity. At the final stage of hypertrophic cartilage
formation transcription of the osteocalcin gene (OC) is initiated and the extracellular
matrix is mineralized (reviewed by (Gerstenfeld and Shapiro 1996). Real time and semi-
quantitative RT -PCR performed on MEF cultures demonstrates that both high-density
culture conditions and the presence of BMP-2 are required for efficient hypertrophy
(Figure 4.3). Cultures not treated with BMP-2 exhibited minimal Coil X gene activity
(Figure 4. A) and were unable to activate AP or OC (Figure 4. , B&C). In monolayer
cultures, BMP-2 modestly stimulated these phenotypic genes. In contrast, the
combination of high-density culture and BMP-2 treatment resulted in a synergistic
activation of CollX , AP, and OC between 6 days and 9 days of culture. The temporal
expression of these phenotypic genes distinctively delineates a second stage of
chondrogenic differentiation achievable by the MEF. Importantly, the chondrogenic
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Figure 4.3: Chondrogenic MEF cultures become hypertrophic. RT-
PCR analysis of collagen X expression, a hallmark of chondrocyte
hypertrophy (A). Alkaline phosphatase expression is a prerequisite
for ECM mineralization. and it is synergistically induced in BMP2
treated micromass cultures (B). Osteocalcin expression is
indicative of a mature. actively mineralizing matrix (C). Indian
hedgehog (lhh) activity is also restricted to BMP2 treated
micromass cultures during the later stages of chondrocyte
maturation. All quantitative PCR data expressed as transcript level
relative to GAPDH transcript level.
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differentiation of MEFs ex vivo reflects the development of the chondrocytic phenotype
from mesenchymal progenitor to hypertrophic chondrocyte. In the growth plate 
in vivo
hypertrophic chondrocytes express and secrete Indian hedgehog (Ihh), a signaling
molecule that acts upon pre-hypertrophic chondrocytes and regulates their rate 
maturation (Long et al. 2001; Kobayashi et al. 2002). Analysis of Indian hedgehog
expression demonstrates that this gene is responsive only to a combination of BMP-2 and
micromass culturing, and it' s induction between 6 and 9 days of culture suggests that
these cultures have entered the hypertrophic pathway, and are limiting the rate of tissue
maturation via the anti-hypertrophic Ihh signal (Figure 4. D). Therefore , induction of
Ihh by cell-cell contact combined with BMP-2 treatment further establishes the necessity
for cooperation of these two signals in the progression of the chondrogenic phenotype.
In order to correlate chondrocyte phenotypic gene expression with the formation of
matUre carilaginous ECM, alkaline phosphatase enzmatic activity was visualized using
a colorimetric assay. Alkaline phosphatase activity was present at low levels throughout
the monolayer in untreated day 10 cultures, while addition of BMP-2 to the monolayer
resulted in more intense AP activity. Untreated micromass cultures exhibited focal AP
activity, while BMP-2 treatment of micromass cultures caused very intense staining
throughout the micromass spheroid, consistent with greater ECM production (Figure 4.4-
A). Next, toluidine blue stain was employed to visualize the negatively charged ECM that
is a hallmark of mature cartilage. Toluidine blue staining only provided contrast to BMP-
2 treated micromass cultures, indicating the presence of a negatively charged ECM. 
visualize the mineralization of the ECM characteristic of the final stage of hypertrophic
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Figure 4.4: BMP2 induced MEF differentiation results in
hypertrophic cartilage formation. Visualization of the ECM
synthesized by MEFs (A). Alkaline phosphatase activity is
detected by colorimetric reaction in the ECM at 10 days of culture
shows intense activity in BMP2 treated Micromass cultures (A, top
panels). Toluidine blue is a metachromatic stain that indicates
total cellularity of MEF cultures and reveals negatively charged
cartilaginous ECM (darker blue staining) in Micromass cultures
treated with BMP2 (A, lower panels). Mineralization of
hypertrophic ECM can be visualized at the final stages of MEF
micromass cultures treated with BMP2. Silver nitrate stains
mineral deposits in the ECM (black) that surrounds individual
chondrocytes in lacunae.
cartilage formation, we performed silver nitrate staining according to the von Kossa
method after 15 days of micromass culture in the presence of BMP-2 (Figure 4.4-B).
This stain reveals that the chondrocytes have acquired a hypertrophic phenotype , as each
individual cell is in a lacuna surrounded by a mineralized extracellular matrix , stained
black.
Runx2 Null MEFs Fail to Mineralize the Cartilaginous ECM
In order to examine the contribution of Runx2 to chondrocyte phenotypic gene
expression MEFs isolated from Runx2 null embryos were induced to undergo
chondrogenesis using BMP2 and high-density culture conditions. We verified an absence
of Run2 protein at all timepoints during differentiation (Figure 4. A). Furhermore, we
observe a co-expression of Runx2 and Runx 1 during the initial three days of culture
(Figure 4. A). Interestingly, observation of Runx2 levels in wildtype cells shows that
Runx2 protein declines concomitantly with the onset of chondrocyte phenotypic gene
expression (Figure 4. B and 4.7). Run2 protein levels are later strongly induced along
with markers of late hypertrophy, alkaline phosphatase and osteocalcin (Figure 4. B and
7). In contrast, Run 1 is induced at the onset of high-density culture and protein levels
are maintained only for the first three days of culture. Runx 1 protein levels were not
affected by the loss of Runx2 (Figure 4. A) suggesting cross-regulation between Runx2
and Runxl does not occur during induction of the chondrogenic phenotype. These results
confirm previous observations of Runx2 expression patterns during chondrogenesis of
C3HI0Tl/2 cells in Chapter 3 in which Runx2 is transiently suppressed in the
Chondrogenic Differentiation of Runx2 -/- MEFs
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Figure 4.5: Chondrogenic differentiation of Runx2 null MEFs.
MEFs were isolated from E12 Runx2 null embryos and their
wildtype littermates and induced to undergo chondrogenesis 
response to high density micromass culture in the presence 
8MP2. Whole cell extracts were analyzed by western blotting at
various timepoints demonstrates a decrease in Runx2 protein at
the onset of chondrogenesis in wildtype cultures, and a total
absence of Runx2 protein in null MEFs (A). Runx1 protein in these
cultures is dramatically induced at the beginning of the culture
period and then declines as cultures mature (A). Analysis of pro-
chondrogenic trranscription factor expression by quantitative RT-PCR (8) indicates that Nkx3. activation is abrogated in the
absence of Runx2 (8).
mesenchymal progenitor cell as it enters the chondrogenic lineage in response to BMP
treatment and high-density culture conditions.
When analyzing expression of chondrocyte phenotypic genes in the absence of Runx2 , it
became evident that Nkx3.2 levels were decreased in the absence of Runx2 (Figure 4.
B), supporting our previous results in C3H10T1/2 cells in Chapter 3 demonstrating that
adeno-viral mediated overexpression of Runx2 induces the Nkx3.2 gene. Although lack
of Runx2 activity did not influence expression of Sox 9 or collagen type II on a per cell
basis (Figure 4.5- Band 4.7), its absence appeared to result in the formation of a larger
cartilaginous area, as evidenced by alcian blue staining (Figure 4. A), indicating that the
absence of Runx2 activity in these cells results in increased proliferation prior to the
onset of differentiation. Durng the final stages of chondrocyte hypertrophy, Runx2 null
MEFs were unable to activate osteoca1cin or alkaline phosphatase, genes known to be
dependent on Run2 activity for their expression (Figure 4.7). Interestingly activation of
type X collagen (a marker of early hypertrophy) stil occurred in the absence of Runx2.
This finding is in contrast with previous findings that have suggested that collagen type X
expression is dependent on the combined activities of Runx2 and BMP2. These findings
provide new insight into the precise point of action of Runx2 during chondrogenic
differentiation and suggest that Runx functions to mineralize the ECM of hypertrophic
chondrocytes by supporting the activity of genes related to mineralization such as
alkaline phosphatase and osteoca1cin similarly to the way Runx2 supports the activity 
these genes during the mineralization of osteoblast-generated ECM.
Day 3
Runx2 +1+
+ BMP2
Runx2 
+ BMP2
Runx2 +/+
or 
- BMP2
Day 3 
Runx2 +1+
+ BMP2
Runx2 
+ BMP2
Day 6 Day 9
iD:
. " . .
II;,
Day 6 Day 9
ili:'
Figure 6: Cartilage formation by Runx2 null MEF cultures. Alcian
blue incorporation into chondrogenic Runx2 null and wildtype MEFs
cultured at high density in the presence of BMP2 (A. upper and
middle panels). In the absence of BMP2, there is no cartilaginous
ECM production from either Runx2 wildtype or null high-density
MEF cultures (At lower panels). Alkaline phosphatase (AP)
enzymatic activity in BMP- treated high-density MEF cultures
demonstrate the requirement for Runx2 in efficient AP production
(B).
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Figure 4.7: Extracellular matrix gene expression in chondrogenic
Runx2 wildtype and null MEF cultures. The absence of Runx2 has
little effect on chondrocyte-specific genes collagen type II (A.
circles) and collagen type X (A. squares). Genes associated with
mineralization of the chondrocyte ECM such as osteocalcin (B.
circles) and alkaline phosphatase (B. squares) are not activated in
MEF cultures nullzygous for the Runx2 gene.
RunxlActivity does not Contribute to Chondrocyte Phenotypic Gene Expression
We next examined the effects of Runx1 loss to the process of chondrogenesis. In order to
bypass the early embryonic lethality or Runx1 deletion 
in vivo we harvested MEFs from
Runl conditional mice (Runxl flox/flox, kindly provided by Dr. Nancy Speck, Darouth
NH) and their wildtype littermates and infected them with Cre-expressing adenovirus
(Ad-Cre) prior to chondrogenic induction. Cre-expression in Runx 1 flox/flox MEFs results
in a complete loss of Runxl activity in these cells (Figure 4. A). In contrast to Runx2
null MEFs, Runxl null MEFs were able to activate all phenotypic genes (Sox9, Nkx3,
Figure 4. B and collagen type II&X, OC, and AP, Figure 4. A) comparable to wildtype
MEFs at all stages of chondrogenesis on a per cell basis. Collagen type X appears to
maintain increased activity at the 9 day timepoint in Runx2 knockout cultues cultures in
comparison to wildtype cultues for reasons not understood. Runxl null cells
, however
formed significantly smaller carilaginous nodules as assessed by alcian blue and alkaline
phosphatase staining (Figure 4. B) These findings suggest that the Runxl induction
observed at the onset of high-density culture (Figure 4. A, time 0) supports the
, proliferative expansion of mesenchymal cells or pre-chondrocytes prior to differentiation.
Our results thusfar suggest that Run 1 and Runx2 perform distinct functions during the
mesenchymal chondrogenesis.
To rule out any possibilities that Runx1 and Runx2 cooperate during mesenchymal-
chondrogenic differentiation, we isolated MEFs from Runx2-/- Runxl
x/flox mouse
embryos and infected them with Cre-expressing adenovirus during proliferative
-8 Wt+Ad-Cre 
-+ 
Runxtflx/flx+Ad-Cre
3.5
1.5
a-\;
--Sox9 WT
--Sox9 KO
Nkx3. VoT
1.S ;'A- Nkx3. 2 KO
;'''=
Figure 4.8: Chondrogenesis of Runx1 null MEFs. Runx1 conditional
MEFs were infected in vitro with aCre-containing adenovirues prior to
initiation of the experiment. Quantitative RT -PCR shows an absence
of Runx1 message in Cre- infected cultures when compared to LacZ-
adenoviral infected controls (A). Cre-infected cultures are therefore
treated as Runx1 null, and LacZ-infected cultures as wildtype.
Analysis of pro-chondrogenic transcription factor gene expression in
Runx1 wildtype or null cultures indicate Runx1 loss has no effect on
the expression of these genes.
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Figure 4.9: Extracellular matrix formation and gene expression in
Runx1 null and wildtype MEF cultures. Analysis of ECM gene
expression (Coli 2 Coli X and DC) indicates that Runx1 loss
does not affect their activity (A&8). Alcian blue staining for
sulfonated proteoglycans and colorimetric staining for alkaline
phosphatase activity reveals significantly smaller cartilaginous
nodules in the absence of Runx1 (C).
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Figure 10: Chondrocyte phenotypic gene expression is not
dependent on cooperation between Runx1 and Runx2. Runx2-
Runx1floxlfox MEFs were infected with the Cre adenovirus in order to
inactivate Runx1 followed by high-density culture and BMP2
treatment to promote chondrogenic differentiation. These cultures
progress through chondrogenesis despite the lack of both of these
Runx factors.
expansion to ablate Runxl activity ex vivo. 
These cells were subsequently induced to
undergo chondrogenic differentiation in high-density cultures treated with BMP2.
Quantitative RT-PCR analysis of these cultures demonstrates that these Runx factors do
not cooperate to drive chondrogenic differentiation, as they remain able to activate
chondrocyte-phenotypic genes collagen type 2 , collagen type X, and Nkx3.2 (Figure
10). These findings support our previous observations suggesting that Runxl and
Runx2 play distinct, non-redundant roles during the chondrogenic differentiation of
undifferentiated mesenchymal progenitor cells.
DISCUSSION
The results of this study demonstrate that the mouse embryonic fibroblast has the ability
to undergo a complete program of chondrogenic differentiation resulting in the formation
of a cartilaginous spheroid ex vivo. These cells begin as undifferentiated, rapidly
proliferating fibroblast- like cells, that then readily differentiate into chondrocytes in
response to BMP-2 and high density culture conditions. The MEFs produce a true
carilaginous extracellular matrix, and finally reach a state of hypertrophy, mineralizing
the ECM. These events recapitulate chondrocyte maturation during endochondral bone
formation in vivo.
The finding that neither BMP-2 nor cell-cell contact alone are sufficient to drive
chondrogenesis demonstrates the importance of cooperation between 3-dimensional
extracellular contact and soluble BMP-2 signaling in the formation of cartilaginous
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tissue. The culture conditions that promote the differentiation of these cells have striking
effects on the transcriptional regulation of chondrocyte-specific transcription factors
Nkx3. 2, Sox9 and Indian Hedgehog. In vivo, BMP2 regulates both initiation of
chondrogenic differentiation through Nkx3.2 (Murtaugh et al. 2001; Zeng et al. 2002),
which is the earliest marker of a pre-chondroyte and a pre-requisite for activation of
Sox9, as well as the rate of hypertrophy through Indian hedgehog (Pathi et al. 1999; Zeng
et al. 2002). Thus, the finding that the BMP2 signal is required in addition to high-
density culture for the chondrogenic differentiation of MEFs suggests that these cells are
in a pluripotent, undifferentiated state while proliferating ex vivo. In contrast, previous
studies using limb bud derived cells as a model of chondrogenesis respond to high
density culture conditions and do not require the BMP2 signal, indicating that limb bud
cells may already be committed to the chondrocyte lineage.
In vivo, hypertrophic chondrocytes secrete Indian hedgehog, which acts upon
chondrocytes in the growth plate in order to attenuate the rate of hypertrophy. Under our
culture conditions, MEFs have the ability to complete the program of chondrocyte
maturation within 9 days of culture and express hypertrophic markers such as collagen
type X, alkaline phosphatase, and osteocalcin, which have all been detected in cells of
mineralized cartilage in vivo. Importantly, mature chondrocytic MEF cultures express
the soluble regulator of the rate of hypertrophy, Indian Hedgehog, reflecting the fidelity
of signaling events that occur during chondrocyte differentiation 
in vivo.
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Recent findings from our group and others (see Chapter 3) have demonstrated that the
Runx family of transcription factors is expressed in undifferentiated mesenchymal
progenitor cells prior to the onset of skeletogenesis in vivo. Studies from our group have
demonstrated that overexpression of Runx2 in C3HI0T1I2 cells prior to the induction of
chondrogenesis with high-density culture and BMP-2 results in inhibition of cartilage
formation, suggesting that Runx2 suppression at the onset of chondrogenesis may be a
pre-requisite for differentiation. Further studies in our lab examining the expression of
Runx 1 during chondrogenesis in vivo demonstrated that this family member is co-
expressed in mesenchymal condensations along with Runx2 , but unlike Runx2, Runxl
expression continues in active chondroblasts, as well as in the perichondrium (a source of
chondro- and osteoprogenitor cells). Utilizing the MEF model system of chondrogenic
differentiation, we have examined changes in Runl & 2 expression and protein levels as
well as the functional consequences of nullizygosity for either or both of these proteins
durng entr into the chondrogenic lineage
We demonstrate that Runx2 protein levels decrease during entry of wildtype MEFs into
the chondrogenic lineage, followed by a strong induction of Runx2 protein and message
during chondrocyte hypertrophy. Furthermore , we demonstrate that MEFs lacking
Runx2 enter the chondrogenic lineage and form cartilage ex vivo more efficiently than
their wildtype counterparts. While chondrogenic ECM gene expression is unaltered in
Runx2 null MEFs on a per cell basis, these cells form larger chondrocytic nodules
indicating that more cells are entering the chondrogenic lineage. The observation that
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Runx2 null MEFs express significantly lower levels of Nkx3.2 during chondrogenesis is
consistent with our previous observations in Chapter 3 demonstrating that overexpression
ofRunx2 in C3HI0Tl/2 cells increases Nkx3.2 gene expression. These findings support
the hypothesis that Runx2 acts to negatively regulate entry of mesenchyme into the
chondrogenic lineage. Further, our results provide evidence for the existence of a
feedback loop between Runx2 and Nkx3.2 in which Nkx3.2 acts to suppress Runx2 in
order to drive chondrogenesis: in the absence of Runx2 , Nkx3.2 levels are reduced
whereas high levels of exogenous Runx2 induce Nkx3.2 expression for the progression of
the chondrogenic phenotype.
Unlike Runx2 , Runx 1 protein levels increase at the onset of chondrogenesis, then
gradually decline as chondrocyte maturation progresses. This observation suggests that
Runx1 may playa positive role during the induction of mesenchymal chondrogenesis
and MEFs lacking Runxl form less carilage ex vivo that wildtype cells. Taken together
our findings indicate that Runx 1 and Runx2 have distinct functions during carilage
formation. This hypothesis is supported by our observation that MEFs lacking both
Runx 1 and Runx2 are stil able to undergo chondrogenic differentiation, ruling out the
possibility that these two factors cooperate to drive chondrogenesis.
The capability of the MEF to undergo chondrogenesis makes it a powerful tool for
analyzing the contribution of specific genes to the process of chondrogenesis and
particularly applicable to the study of genes whose alteration results in embryonic
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lethality in genetically altered mice. The ability of the embryonic fibroblast to be
expanded ex vivo makes it particularly attractive for generation of cartilage, since mature
chondrocytes are difficult to isolate and reluctant to proliferate while maintaining the
chondrocytic phenotype ex vivo (Kuriwaka et al. 2003; Malpeli et al. 2004). Previous
studies have characterized adipogenic differentiation of MEFS (Alexander et al. 1998;
Yun et al. 2002; Landsberg et al. 2003). Here our studies establish the MEF as a
pluripotent cell by demonstrating its ability to enter a second differentiation pathway,
chondrogenesis. A source of human embryonic fibroblasts may someday allow us to
generate cartilage for therapeutic purposes through the advances of molecular/cell
biology and tissue engineering.
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Chapter 
Targeted Inactivation of Runx2 Type II
;.,
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INTRODUCTION
The Runx family of transcription factors exhibits a high degree of homology in their
DNA binding domains and their genomic structure. The three mammalian Runx genes
each encode two major isoforms that are controlled by two distinct promoter regions (i.
PI and P2), with approximately 80 kb of genomic sequence separating their respective
star codons. The upstream isoform, termed Type II , or til- initiates with the amino acid
sequence MASNS and is driven by the PI promoter, while the downstream isoform
termed Type I , initiates with the amino acid sequence MRIPV and is driven by the P2
promoter. These isoforms differ only in the utilization of one additional exon in the Type
II isoform that becomes spliced to downstream exons common to both isoforms. This
additional exon makes the Type II isoform 19 amino acids longer than Type I, although
these additional amino acids serve no known function (Harada et al. 1999; Banerjee et al.
2001). We speculate that the evolution of two promoter regions reflects a demand for a
higher order of transcriptional regulation, and that co-expression of both Type I and Type
II isoforms in mature osteoblasts meets a requirement for differential regulation of Run2
protein during distinct stages of skeletal development (Choi et al. 2002).
Towards gaining further insight into the regulation and function of the Runx2 Type II
isoform, we have generated a knock-in mouse model in which exon 1, the only coding
region unique to the Type II isoform, is replaced with the Lac- reporter gene. This
model wil allow for analysis of the functional contribution of this isoform to
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skeletogenesis while also providing an in situ 
reporter assay for the examination of PI
promoter activity in its native context. Preliminar analysis of these mice indicates that
the lac- reporter gene is indeed expressed in mature osteoblasts that are actively forming
new bone. The ex vivo culture of osteoprogenitor cells derived from these mice wil
enable the study of the responsiveness of the endogenous upstream PI promoter to a
variety of cytokines and growth factors, and, in particular, BMP- , whose activity is
known to elevate Runx2 message and protein levels in osteoprogenitor cells 
in vivo. The
mechanism by which BMP2 elevates Runx2 remains elusive as 
in vitro and transgenic
studies (see Chapter 2) aimed at analyzing activity of the proximal 3 kb segment of the
Runx2 PI promoter have demonstrated that the BMP-2 responsiveness and osteogenic
specificity of this promoter do not lie within this region. While a phenotypic analysis of
a similar Runx2 Type II null animal has recently been published (Xiao et al. 2004), we
are pursuing the analysis of homozygous Type II knockin mice independently because
there are critical differences in the two targeting approaches that may influence the
outcome of the results.
MATERIALS AND METHODS
Cloning
Genomic DNA for use in the Runx2 Type II targeting vector was isolated from AB2.
murine embryonic stem cells. Target DNA for generating arms of homology was
amplified using Pfu ultra DNA polymerase (Invitrogen) and polymerase chain reaction.
Genomic DNA fragments used for arms of homology in the targeting vector were ligated
to the LacZ reporter gene , the PGK-neomycin positive selection marker, and the PGK-
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thymidine kinase negative selection marker (Figure 5.1) (all kind gifts from Dr. Stephen
Jones, University of Massachusetts Medical School) using T4 DNA ligase (Invitrogen).
The final targeting vector was created using the pBluescript vector backbone
(Stratagene ). Transformation of constructs was carried out using XL- I0 Gold
ultracompetent E. coli (Stratagene). Ultimately, 10 lAg of complete targeting vector was
linearized and electroporated into 1XI0 AB2.2 murine embryonic stem cells followed by
positive and negative selection. Resulting clones were then cultured in 96 well plates in
duplicate. One set of duplicate plates was screened by Southern blot for successful
homologous recombination using an external 3' probe and PCR-based analysis (See
Genotyping section and Figure 5.2). Properly targeted clones were isolated from the
second set of duplicate plates , expanded, and used in blastocyst injections performed by
the University of Massachusetts Medical School Gene Targeting Core Facility. Resulting
chimeric mice were backcrossed to wildtype B6 mice until germline transmission was
achieved. These crosses yielded one female mouse heterozygous for the til-l knock-
(TK) allele. This founding female was backcrossed to a wildype B6 male to expand the
colony.
Genotyp;ng
ES cells and mice were genotyped by Southern blotting and PCR. Genomic DNA was
isolated from cells or mouse tissue after overnight incubation at 55 C in lysis buffer
containing proteinase K. DNA was then isolated by phenol-chloroform extraction.
Following purification, genomic DNA was resuspended in TE buffer, pH8, and was
either digested for Southern blotting used template for
108
Native Locus
--..- 
1 FM:;.k;jii;\f,(j;:i;,
\;;
O%'
''; ' "';;";
rOff:g;;'
;:;
iPl:;
~~~ ~~~;.,:, ,. "
3 kb
''.
'0'''
:;"
c: 
 "
'" A 
"  .
S:...
. . 
Targeting Vector 1 .
.....
':' PGK-Neo ' "
~~~
fMJtK'2 kb 2.2 kb
Protein Products 
Figure 5.1: Targeting strategy for gene replacement of Runx2
Type II exon 1 with the LacZ reporter gene. The targeting vector
contains a 2.2 kb 3' arm of homology and a 3 kb 5. arm of
homology which partially encompasses the Runx2 P1 promoter (3
kb P1). The LacZ reporter gene and a Neomycin drug resistance
gene flanked by loxP sites were inserted between the arms of
homology, that, upon homologous recombination with the wildtype
allele, replace exon 1 as well as the splice donor site required for
splicing into downstream exons common to Runx2 Type I and II.
The targeted allele produces I galactosidase as a result of P1
promoter activity and Runx2 Type I as a result of P2 promoter
activity.
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I " PCR. Southern blotting for the presence of the targeting construct was done using an
internal probe against the LacZ reporter gene (Figure 5. , IP). Verification of
homologous recombination was performed by southern blotting using BamHI digest and
an external probe that lies in the intronic region outside of the 3' ar of homology at the
Runx2 locus (Figure 5. , EP). This probe picks up a 15 kb genomic BamHI fragment
on the wildtype allele , and a smaller 7 kb fragment resulting from the introduction of a
BamHI site from the neomycin cassette after homologous recombination on the mutant
allele (Figure 5- , panel A). Homologous recombination was verified at the 5' terminus
of the targeted allele m;ing PCR primers extending from just upstream of the 5' terminus
of the 5' arm of homology into the LacZ coding region (Figure 5. , 5' lacZ PCR).
Routine genotyping was then carried out using two sets of PCR primers. The first
amplifies the tageted exon in the wildtype allele (Figure 5.2, Exon1 PCR) (F: -atg ctt
cat tcg cct cac aaa c- , R: 5' -ccc aaa aga agc ttt gct gac- ), generating a product in
both wildtype and heterozygotes. The second amplifies the LacZ coding region (Figure
5.2 , lacZ PCR) (F: -cca act taa tcg cct tgc agc aca tc- , R: -cgt ggg aac aaa cgg
cgg att gac- ), generating a product in both heterozygotes and nullizygotes (Figure 5.
B).
Histological Analysis
Newborn mice were sacrificed by decapitation and eviscerated followed by overnight
fixation in a solution containing 2% paraformaldehyde, 0.2% glutaraldehyde, 5 mM
EGT A, 2 mM MgCh, and 0. 1 M PBS. Whole embryos or individual skeletal elements
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were then stained for f)-galactosidase activity. Whole mount images of f)-gal staining
were taken prior to dehydration in a graded ethanol series and infitration with paraffin
wax. Histological sections were taken at 10 flm and mounted on glass slides with
Permount mounting media. Ex vivo osteoblast cultures were fixed in 
paraformaldehyde for 10 minutes at room temperature and stained for f)-gal activity or
alkaline phosphatase activity directly in 6-well tissue culture plates. alkaline phosphatase
activity was visualized in cultures by exposure to a solution containing 0. 5 mg/ml
Napthol as MX Phosphate (disodium salt), 1 mg/ml Fast Red salt, and 2. 8% N
dimethyl formamide in 0. 1 M Tris maleate buffer, pH 8.4 for 15 minutes at 37 C in the
dark. All chemicals were obtained from Sigma Chemical , Madison, WI except where
indicated.
Primary Calvarial Osteoblast Cultures
Calvarial osteoblasts were isolated from E19 embryos by enzmatic digestion of calvaral
bones. Briefly, calvaria were minced and subjected to three sequential digestions (8, 10
and 26 min) with collagenase P (Roche Molecular Biochemicals, Indiana, IN) at 37
Osteoblasts in the second and third digest were collected and resuspended in a-MEM
supplemented with 10% FBS (Hyclone). Cells were plated at a density of 1 x 10
cells/six-well plate (Owen et al. 1990). Differentiation was initiated post-confluence by
the addition of ascorbic acid and f)-glycerol phosphate. Cultures were harvested at
various timepoints and stained for f)-galactosidase activity.
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Figure 5.2: Genotyping strategy for identification of the Runx2
Type II- LacZ allele. The presence of the targeting vector in ES
cells after selection with neomycin and G418 was confirmed by
Southern blotting with an internal probe against the LacZ gene
(IP). Homologous recombination was then confirmed at the 3' end
of targeted allele by Southern blotting BamHI digested genomic
DNA with an external probe (EP). Homologous recombination
was confirmed at the S' end of the targeted allele using a genomic
PCR strategy (S' lacZ PCR) in which the forward primer lies
outside the S' terminus of the S' arm of homology and the reverse
primer lies within the coding sequence of the 
LacZ gene. Routine
genotyping of the mouse colony was carred out using two PCR
reactions. The first (Exon1 PCR) detects the presence of Runx2
exon 1, and the second (lacZ PCR) detects the presence of the
LacZ gene.
112
RESULTS
Homozygosity for the TK Knock-in Allele does not Result in Embryonic Lethality
To determine whether the introduced mutation results in an embryonic lethal phenotype
several pregnancies resulting from the mating of heterozygous mice were brought to
term, and resulting litters were analyzed for the absence of the Runx2 Type II exon 
(Figure 5. , panel B). Nullizygous mice were born at the expected Mendelian ratios
demonstrating that loss of Runx2 Type II does not result in embryonic lethality (Figure
5.3, -/-). Further, Runx2 Type II null mice form a complete mineralized skeleton that
exhibits no apparent defects. We continued to monitor the development of Runx2 Type
II null mice and their wildtype littermates, and by two months of age all of the
nullizygous mice were visibly smaller than their wildtype littermates, indicating that loss
ofRun Type II does affect the maintenance of body mass in mature mice (Figure 5.4).
The underlying physiological cause of the observed decrease in body mass is under
investigation. These findings demonstrate that Runx2 Type II is not essential for
development or skeletal formation, but may playa role later in life. Our findings are
conflcting with those of Xiao et al. who report lethality within the first 2 weeks post-
partum due to the absence of Runx2 Type II (Xiao et al. 2004). This group was,
however, unable to identify the cause of lethality.
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Figure 5.3: Genotyping of the Runx2 Type II-LacZ allele.
Southern blotting of genomic DNA derived from ES cells that have
passed both positive (neomycin) and negative selection for the
presence of a correctly targeted knock- in allele (A). Genomic DNA
was digested with BamHI and hybridized with the extemal probe
pictured in figure 5.2 (EP). The wildtype allele (WT) yields a 15 kb
band, while the targeted allele yields a 7 kb band resulting from
the introduction of a BamHI site from the targeting vector. Routine
genotyping of the Runx2 Type II-LacZ mouse colony by PCR
amplification of Runx2 exon 1 and LacZ (8). Wildtype mice 
(+/+)
are positive only for exon 1, heterozygotes (+1-) are positive for
both exon 1 and LacZ. and homozygous knock-in mice 1-) are
positive only for the LacZ gene.
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Figure 5.4: Deletion of Runx2 Type II results in decreased body
mass. Pups from 5 litters of Runx2 Type 1I"'/ LacZ X Runx2 Type
U"'/UlCZ matings were were weighed at one month of age. Runx2
Type IIUlcZ'LacZ (knockout) mice were consistently smaller than their
wildtype or heterozygous littermates.
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Replacement of Runx2 Exon 
with LacZ results in Osteoblast-specifc fJgalactosidase
Activity.
In order to evaluate the effects of various signaling molecules on Runx2 PI promoter
activity, we replaced the only exon unique to Runx2 Type II with the 
LacZ reporter gene
(Figure 5. 1). Whole mount staining of newborn tissues for f)-galactosidase activity
indicates that expression of the Runx2 PI promoter is limited to mineralized skeletal
elements, including bones formed by both intramembranous (Figure 5.5, Calvaria) and
endochondral ossification (Figure 5. , Ribs, Sternebrae). Examination of soft tissues and
embryos prior to skeletogenesis revealed no additional sites of promoter activity (data not
shown). Histological sections of longbones (Figure 5.6) reveal f)-gal positive osteoblasts
(OB) lining the bone surface beneath the periosteum (PO). The positioning of these
osteoblasts along the bone surface indicates that these cells may be actively involved in
bone formation. Interestingly, osteoblasts that have become embedded within the
mineralized matrix of the cortical bone (CB) thereby becoming osteocytes (OCY) are
negative for f)-galactosidase activity.
Runx2 Type II Expression is Restricted to the Later Stages of Osteoblast Maturation.
To further define the time frame in which the Runx2 Type II gene is expressed
, bone
marrow stem cells (BMSC) were harvested from 6-week old Runx2 Type II 
+/LacZ mice
and culture ex vivo. None of these cells were f)-galactosidase positive after the initial 4-
day period of adhesion. We next induced osteogenic differentiation in confluent cultures
of BMSCs by the addition of ascorbic acid and inorganic phosphate to the 
cultues. No
116
Ribs Calvaria Sternebrae
Figure 5: Whole mount analysis of newborn Runx2 Type II 
+/lacZ
mice reveals restricted galactosidase activity in mineralized
tissues. X-gal staining of organs and skeletal elements reveals that
LacZ expression is limited to the mineralized skeleton, including
bones formed by endochondral ossification (Ribs and Sternebrae)
and bones formed by intramembranous ossification (Calvaria).
,.,
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Figure 6: Histological analysis of longbones isolated from
newborn Runx2 Type II 
+/LacZ demonstrating the specificity for
Runx2 Type II expression in mature osteoblasts. Longbones
stained with X-gal were sectioned and counterstained with Eosin to
reveal mineralized cortical bone (CB). LacZ positive osteoblasts
(OB) were seen localized to the cortical bone surface below the
periosteum (PO). Osteocytes (OCY) embedded in the mineralized
matrix are LacZ negative.
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Figure 7: Ex vivo culture of primary bone marrow stem cells
induced to undergo osteogenic differentiation demonstrates that
Runx2 Type II expression is limited to the most mature
osteoblasts in mineralizing nodules. X-gal staining of
osteogenic BMSC cultures reveals clusters of LacZ positive
osteoblasts (left panels) that are at the center of multilayered
colonies which exhibit strong alkaline phosphatase activity (right
panels).
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f)-galactosidase positive cells were observed until several days after the formation of
multilayered osteoblast nodules. In these multilayered nodules, we observed Run Type
II gene activity only in the most matue cells residing in the center of the nodules (Figure
7, left panels). The presence of high levels of alkaline phosphatase concentrated in the
center of the f)-galactosidase positive osteoblasts supports in vivo observations indicating
that Run Type II gene activity is restricted to activated osteoblasts involved in mineral
deposition (Figure 5. , right panels).
DISCUSSION
Here we report on the generation of a mouse model in which the Type II , bone-related
isoform of Runx2 is replaced by the LacZ coding sequence. This model has allowed us
to assess the contribution of this isoform to the process of skeletogenesis and , more
importantly, has created a reporter allele for readout of endogenous Runx2 PI promoter
activity. Our results demonstrate that this particular Runx2 isoform is dispensable for
embryonic development and for skeletal formation. This result is not surprising since
several studies have demonstrated that Run2 Type I and Run2 Type II are co-expressed
in most skeletal progenitor cells during development (Sudhakar et al. 2001; Chen et al.
2002; Choi et al. 2002). Further, mice homozygous for the Runx2 Type II exon
replacement develop to maturity, but exhibit reduced body length and mass in
comparison to their wildtype littermates. The cause of this defect, and whether it is
related to osteoblast differentiation and skeletal maintenance is under investigation.
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Interestingly, our findings differ from those of Xiao et ai. (Xiao et ai. 2004) who report
that deletion of Runx2 Type II results in a high rate of perinatal lethality (80% lethality
by day 1). The mice generated by this group present with decreased body mass similar to
that observed in our animals , and also exhibit minor defects in bone formation,
' -
particularly in trabecular bone. The skeletal defects observed by Xiao et al are not
sufficient to explain the observed lethality raising the question as to what is the cause of
death in their mouse model, which seemingly exhibit phenotypic normalcy otherwise. It
is possible that the mild skeletal phenotype observed by Xiao et ai. is due to
compensation by the downstream Runx2 Type I isoform as Runx2 Type II knockout
animals do exhibit an approximately 30% increase in Runx2 Type I mRNA levels.
Whether our animals wil exhibit similar defects in trabecular bone formation remains to
be determined and necessitates micro-CT (3-dimensional X-ray microtomographical
reconstrction) analysis.
Unlike the mouse model generated by Xiao et aI. , our mouse model harbors the LacZ
coding sequence thereby facilitating the analysis of endogenous Runx2 PI promoter
activity. We demonstrate here that the LacZ allele becomes activated only in the most
mature , active osteoblasts in the developing skeleton and in primary osteoblast cultures
ex vivo. This result is consistent with findings in the literature demonstrating that the
transcript derived from the PI promoter is restricted to mature osteoblasts (Park et al.
2001; Sudhakar et al. 2001; Choi et al. 2002). The generation of the Run2 Type II-LacZ
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allele wil be an invaluable tool for the identification and functional analysis of factors
that modulate Runx2 gene expression and skeletogenesis.
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Chapter 6:
Activity of the Mdm2 Oncogene Supports Runx2
Expression and Osteoblast Differentiation During
Embryonic Skeletogenesis
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ABSTRACT
The Mdm2 oncogene can promote cell proliferation through it's ability to negatively
regulate the activity of the p53 tumor suppressor. Loss of Mdm2 results in p53
accumulation and ultimately results in exit from the cell cycle or apoptosis. Mdm2 null
mice exhibit early embryonic lethality that can be rescued by deletion ofp53. Mdm2/p53
null mice are phenotypically normal, indicating that the primary function of Mdm2 is to
regulate p53. We have observed an increase in Mdm2 expression during the process of
osteoblast differentiation that has led us to examine the role of Mdm2 during the process
of skeletogenesis. To address this question, we have utilized a murine genetic system for
tissue-specific Mdm2 ablation. In this system a conditional Mdm2 allele (Mdm2 flox) is
excised during embryogenesis by Cre recombinase under control of the type I collagen
promoter (Coil I-Cre). We find that deletion of Mdm2 in pre-osteoblasts upon activation
of the ColI I -Cre transgene results in impaired skeletal formation. Bones of Mdm2 
flox/flox
CoIl I-Cre (Mutant) embryos are shorter, exhibit increased porosity, and have less
mineral content than their Mdm2 flox/+ Coil I-Cre (Wildtype) littermates. To characterize
the molecular basis for the decreased bone quality observed in these animals, we isolated
calvarial pre-osteoblasts and induced them to differentiate 
ex vivo. In these cultures
mutant pre-osteoblasts proliferate identically to pre-osteoblasts isolated from wildtype
littermates and both cell types reach confluence concomitantly. In post-confluent
cultures, however, the Coll I-Cre transgene becomes active in multilayering pre-
osteoblasts resulting in Mdm2 excision and subsequently preventing the increase in
Mdm2 expression observed in wildtype cultures. The loss of Mdm2 in these cells
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prevented multilayered nodule formation 
ex vivo due to inhibition of post-confluent cell
division. Further, mutant cultures that have ablated Mdm2 activity fail to activate the
master osteogenic transcriptional regulator Run2, and therefore do not induce osteoblast
associated phenotypic genes such as alkaline phosphatase and osteocalcin. Thus , Mdm2
is genetically upstream of the mechanism mediating the bone-specific induction of
Runx2. In addition, Mdm2 performs a novel osteogenic function that supports
progression of osteoblast differentiation and post-confuent nodule formation.
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INTRODUCTION
The Mdm2 proto-oncogene was initially identified due to its amplification on mouse
double minute chromosomes present in spontaneously transformed 3T3 cells (Cahily-
Snyder et al. 1987). Initial investigations by the Oren and Levine laboratories identified
Mdm2 as a binding partner for p53, and subsequent work from these groups revealed that
Mdm2 negatively regulates p53-induced transcription of the Mdm2 gene. During times
of cellular insult, p53 activates Mdm2 gene expression by binding to a p53 response
element within the first intron of the Mdm2 gene (Juven et al. 1993). Induction of Mdm2
protein levels lead to an increase in Mdm2-p53 complex formation that interferes with
the ability of p53 to transactivate target genes, including Mdm2. Thus, Mdm2 not only
regulates p53 activity, but by doing so also regulates its own gene expression. Mdm2 has
been shown to inhbit p53 in several ways. First, Mdm2 can interfere with the ability of
p53 to transactivate target genes by binding to and stearically hindering the N-terminal
activation domain of the p53 protein (Juven-Gershon and Oren 1999). Secondly, Mdm2
can function as an E3 ligase to coordinate the monoubiquitinlylation of p53, which in
turn acts as a signal for polyubiquitinylation by other factors such as p300/CBP
(Grossman et al. 1998; Lai et al. 2001). Finally, Mdm2 shuttles polyubiquitinylated p53
from the nucleus into the cytoplasm where it is degraded by the 26S proteosome
(Freedman and Levine 1998). The importance of Mdm2 in negatively regulating p53
activity is perhaps best ilustrated by the finding that the early embryonic lethal
phenotype of Mdm2-null mice can be fully rescued by the concomitant deletion of p53
(Jones et al. 1995).
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Given the importance of p53 as the principal ' guardian of the genome ' during times of
DNA damage and cellular insult, it is not surprising that inactivating mutations in the p53
gene frequently result in tumor formation. The intimate relationship between Mdm2 and
p53 therefore suggests that the activity Mdm2 may also be affected in cancers , and in fact
, ,
recent findings have demonstrated that deregulated Mdm2 gene expression serves as an
initiating event for tumor development. Gene amplification and overexpression of Mdm2
have been shown to transform cells, disrupt coupling of S-phase to mitosis, interfere with
cell cycle arrest and apoptosis, as well as induce tumor formation in vivo (Leach et al.
1993; Lundgren et al. 1997; Jones et al. 1998; Barel et al. 2002). These findings have
made Mdm2 an attractive target for cancer therapeutics. Small-molecule inhibitors
known as 'Nutlins ' developed by Hoffman- La Roche (Basel , Switzerland) have been
shown to bind with high-affinity to the hydrophobic cleft of Mdm2 (a site normally
occupied by p53) and block Mdm2-p53 association to either induce a cell cycle arest or
initiate programmed cell death in tumor-derived cell lines (Vassilev et al. 2004).
Similarly, Hybridon (Cambridge , MA) has generated Mdm2 antisense racemic mixtures
that induce growth arest or apoptosis in prostate cancer cell lines via p53-dependent and
p53-independent mechanisms (Zhang et al. 2003). The drawback of these studies is that
loss of Mdm2 function was not examined in primary cell lines or normal tissues 
in vivo.
If Mdm2 loss is detrimental to normal tissue, is Mdm2 inhbition a feasible strategy for
tuor suppression in vivo?
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Although the importance of Mdm2 regulation of p53 during early stages of
embryogenesis is clear from the apoptotic response that results from Mdm2 loss, little is
known with regards to the requirement for maintaining the p53-Mdm2 autoregulatory
loop in developing tissues later during gestation. Until now knowledge of the
consequences of Mdm2 loss or p53 hyperactivity have been elusive since attempts at
generating p53 overexpressing transgenic mice have resulted in early embryonic lethality,
as does ablation of the Mdm2 gene. Here we describe for the first time the effects of
Mdm2 loss on normal tissue development during murine embryogenesis. We utilize a
conditional Mdm2 allele that becomes inactivated in developing skeletal elements in
response to the activity of a transgene in which Cre recombinase is under the
transcriptional control ofthe type I collagen promoter (Coll-Cre).
Our results demonstrate that there are spatially and temporally specific responses to the
loss of Mdm2. An early (EI0) activation ofthe Coll-Cre trans gene results in a significant
apoptotic response in primitive neuro-progenitor and mesenchymal progenitor cells.
Surprisingly, later activation of the Coll-Cre trans gene (post-E14) in the skeleton does
not result in an apoptotic response, but rather inhibits osteoblast differentiation causing
an osteoporotic phenotype in vivo. 
This phenotype can be attributed to an increase in
activated p53 , which ultimately results in failure of osteogenic precursors to induce the
transcriptional regulator, Runx2 , whose activities are directly responsible for the
activation of osteoblast phenotypic genes and the formation of mineralized tissue. Our
results clearly demonstrate that Mdm2 plays a critical role in the growth and
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differentiation of normal tissues during development, and that the consequences of Mdm2
deletion are cell-type dependent, reflecting a differential requirement for the Mdm2-p53
autoregulatory loop. Our findings suggest that the potential use of Mdm2 inhibitors as
cancer therapeutics may be confounded by the requirement for Mdm2 activity in the
homeostasis of normal tissues.
MATERIALS AND METHODS
Mouse Lines
Mdm2 conditional mIce were developed in our laboratory usmg homologous
recombination. The resulting allele contains two 10xP sites flankng exons 11 and 12.
Upon Cre-mediated recombination, exons 11 and 12 are excised, rendering the allele
inactive (Figure 6. , described in(Steinman and Jones 2002). Mdm2 excision was
mediated by crossing Mdm2 conditional (Mdm2flx/flX) mice to transgenic mice in which
the 3.6 kb type I collagen promoter governs the expression of the Cre recombinase
enzyme (Coll- Cre) (a generous gift from Dr. Barbara Kream at the University of
Connecticut) (Figure 6. A). Visualization of tissues in which the Cre recombinase
activity has recombined target alleles was facilitated by mating Coll-Cre transgenic mice
to R26R reporter mice (Jackson Laboratories, Bar Harbor, Maine) in which Cre
expression results in the removal of a 10xP- flanked DNA segment that prevents
expression of a LacZ gene (Figure 6. A). All animals were appropriately cared for in
accordance with the University of Massachusetts IACUC protocol.
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Whole Mount and Histological Analysis
Embryos were harvested from timed pregnant mothers at various timepoints during
gestation followed by fixation in 4% paraformaldehyde. Tissues destined for histological
sectioning were dehydrated in a graded series of ethanol and xylene, followed by
infitration with paraffin wax. Tissues from R26R1Coll- Cre crosses were fixed in 4%
paraformaldehyde, equilibrated overnight in 30% sucrose, and embedded in OCT for
cryosectioning. Some embryos were fixed in 4% paraformaldehyde followed by whole
mount staining for f)-galactosidase activity. Parrafin sections were cut at 7 m and
counterstained with eosin. Frozen sections were cut at 1 0- 12 , stained for f)-
galactosidase activity, and counter stained with eosin. f)-galactosidase activity was
visualized by staining whole embryos, cryosections, or calvarial cultures in a solution
containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCh,
2% NP- , 0.01% sodium deoxycholate, and 1mg/mL X-Gal in PBS , pH 7.4 at 37
for 1-6 hours. Calvarial cultures and paraffn sections were analyzed for mineral content
using the method ofVon Kossa. Briefly, sections were exposed to a solution of3% silver
nitrite under direct sunlight for 15 minutes after which mineral deposits were visualized
as a black precipitate under bright field microscopy. Alkaline phosphatase activity in
calvarial cultures was visualized by colorimetric enzymatic reaction to a solution
containing 0.5 mg/mL napthol as MX phosphate disodium salt (Sigma), 2. 8% N
dimethylformamide (Sigma), 0. 1 M Tris-maleate buffer (pH 8.4), and Img/mL Fast Red
salt (Sigma). Reaction was carried out at 37 C for 10 minutes. TUNEL staining was
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performed on dewaxed paraffn sections using a flourescein-conjugated in situ cell death
detection kit (Roche) according to the manufacturers protocol.
Skeletal Preparations
Skeletons were prepared for visualization of cartilage and bone using alcian blue and
alizarin red stains , respectively. Embryos were eviscerated followed by overnight
fixation in 100% ethanol. The next day, carilaginous elements were stained overnight in
a solution containing 4 parts ethanol , 1 part glacial acetic acid, and 0.3mg/mL alcian blue
80X (Sigma). The next day, soft tissues were dissolved for 6 hours in a 2% KOH
solution followed by an overnight staining in a 1% KOH solution containing 75 
g/mL
alizarin red S (Sigma). Skeletons were then de stained in 20% glycerol, 1 % KOH for
several days and stored in 50% glycerol 50% ethanol.
Calvarial Osteoblast Preparations
Calvarial osteoblasts were isolated from E 19 embryos by enzmatic digestion of calvarial
bones. Briefly, calvara were minced and subjected to three sequential digestions (8 , 10
and 26 min) with collagenase P (Roche Molecular Biochemicals, Indiana, IN) at 37
Osteoblasts in the second and third digest were collected and resuspended in a-MEM
supplemented with 10% FBS (Hyclone). Cells were plated at a density of 1 x 10
cells/six-well plate (Owen et al. 1990). Differentiation was initiated post-confluence by
the addition of ascorbic acid and f)-glycerol phosphate. Cultures were harvested at
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various timepoints and stained for (3-galactosidase activity, mineral content, alkaline
phosphatase activity, or total cellularity using toluidine blue.
RNA Isolation and Analysis
RNA was isolated from tissue or cell cultures using Trizol Reagent (Invitrogen, Carlsbad
CA) according to the manufacturers protocol. After purification, 5 g of total RNA was
DNAse treated using a DNA-free RNA column purification kit (Zymo Research, Orange
CA). One g of RNA was then reverse transcribed using Oligo-dT primers and the
SuperScript 1 st Strand Synthesis kit (Invitrogen) according to the manufacturers protocol.
Gene expression was assessed by semi-quantitative (Cre, Mdm2, GAPDH, 25 cycles) and
quantitative real-time PCR (Runx2, AP , OC , collagen type I , GAPDH). Quantitative
PCR was performed using SYBR green 2x master mix (Eurogentec, Belgium) and a 2
step cycling protocol (anneal and elongate at 60 C, denature at 94 C). Specificity of
primers was verified by the dissociation temperature of amplicons. Primers used for PCR
reactions are listed in Table 1. Results are representative of two or more independent
experiments.
Protein Analysis
Total protein was isolated from calvarial cultures in the presence of direct lysis buffer
(2% SDS , 10 mM DTT, 10% glycerol , 12% urea, 10 mM Tris/HCI (pH 7.5), 1 mM
PMSF, IX Protease inhibitor cocktail (Roche), 25 M MG 132 proteosome inhibitor)
followed by heating for 5 minutes at 100 C. 40 g total protein was then electrophoresed
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through a 10% acrylamide gel followed by transfer onto a PVDF (Immobilon)
membrane. Membranes were blocked in PBST containing 2% non-fat dry milk (Biorad)
prior to incubation with antibodies. Antibodies were incubated with membranes in the
presence of PBST containing 2% non-fat dry milk 1 hour at room temperature. Excess
primary antibody was removed with three 10-minute washes of PBST. Secondary
antibodies were incubated with membranes for 30min- 1hour at room temperature
followed by three 10-minute washes with PBST to remove excess antibody. Proteins
were visualized on the membrane by exposure to Western Lightning (Perkin Elmer
Wellesley, MA) chemiluminescent reagent. The Runx2 antibody was a generous gift
from Drs. Y oshi Ito and Kosei Ito at the National University of Singapore. All antibodies
were used at a concentration of 50 ng/mL.
RESULTS
Activity of the Collagen Type I Promoter during Embryogenesis
To understand the contribution of the Mdm2 proto-oncogene to the development of
connective tissues, we have utilized a conditional Mdm2 allele in which the majority of
the coding region (exons 11 and 12) is flanked by 10xP recombination sites (Figure 6.
A). Deletion of these exons renders the allele inactive in tissues expressing a transgene in
which the 3.6 kb type I collagen promoter controls expression of Cre recombinase. We
initially verified the expression of Cre in skeletal elements of adult mice to insure that
excision wil occur (Figure 6.1-B). To identify regions in the developing embryo that
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Figure 6.1: Mouse models for tissue-specific deletion of Mdm2
in the developing skeleton. A transgene in which the type I
collagen promoter drives expression of Cre recombinase (A top
construct) was used to excise a stop codon in R26R reporter
mice (A, second construct) as well as to excise exons 11 and 12
of Mdm2 (A, third construct) yielding an Mdm2 null allele (A
fourth construct). Cre expression in the Coll-Cre transgenic
mouse was verified by RT-PCR analysis of RNA isolated from
adult tissue (B).
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have undergone Cre-mediated excision, we bred Coll-Cre transgenic mice to R26R
reporter mice that activate f)-galactosidase in response to Cre recombination. Our
findings demonstrate that this promoter becomes activated at two distinct points during
development. The initial activation of the Coll-Cre transgene occurs early in
development (E9) and is localized to the caudal portion of the embryo (Figure 6.2). This
region of the developing embryo contains both neuroprogenitor and mesenchymal
progenitor cells that are destined to give rise to the caudal axial skeleton and spinal cord.
Later in development (around E 14), the Coll-Cre trans gene undergoes a robust activation
in relation to the formation of connective tissue. This activation results in excision in
both the skin and developing skeletal elements (Figure 6.2). These findings indicate that
the observed biphasic transgene activation wil result in Mdm2 deletion in several tissues
upon crossing the trans gene onto Mdm2 conditional mice.
Early Transgene Activation Results in Loss of Caudal Tissue due to Apoptosis
Having established the pattern of excision caused by expression of the Coll-
Cre
transgene, we crossed Mdm2 conditional (Mdm2
flx/flX) mice to Coll-Cre transgenic mice
containing one conditional Mdm2 allele (Mdm2
flx/+Coll-Cre). The resulting litters
contained Mdm2flx/flxColl-Cre mice that are designated as mutant (MT) as well as
Mdm2flx/+Coll-Cre mice that exhibit no defects and are referred to as wildtype 
(WT).
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Based upon the observation that Cre-mediated excision occurred early in development
we examined the effects of this excision in embryos between EI0.5 and E19.5. Loss of
Mdm2 in this developing caudal region resulted in a complete absence of tissue
surrounding the somites. Embryos exhibited caudal runting, exposure of somitic
mesenchyme at the surface of the embryo , absence of a tail , and a severe invagination in
the posterior dorsal region encompassing the lumbar vertebrae (Figure 6.3). Skeletal
preparations of E 19 embryos revealed highly dysplastic axial skeletal elements in the
mutant embryo with fused cartilaginous lumbar vertebrae that have failed to undergo
turover into mineralized bone (Figure 6.4).
To define the events resulting in malformation of the caudal axial skeleton, E 10 embryos
were sectioned and tissue morphology was examined. At E10 , wildtype embryos had
clearly segmented somites that would give rise to axial skeletal components including
vertebrae and ribs (Figure 6. , arows). The somites are surounded by primitive neural
tissue and developing dorsal root ganglia (Figure 6. , arrowheads). In contrast, mutant
embryos lack developing neural tissue and posterior dorsal root ganglia, leaving somites
externalized. To understand the mechanism underlying this tissue loss, we performed
TUNEL staining on serial sections. Our results show that there is a dramatic increase in
TUNEL-positive apoptotic cells in the caudal somites and surrounding tissue of mutant
embryos in comparison to wildtype littermates. These observations are consistent with
well established findings demonstrating that Mdm2 loss induces p53-mediated apoptosis
early in development of the mamalian embryo (Jones et al. 1995).
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Figiure 2: Lineage tracing of cells expressing the Coll-Cre
transgene during embryogenesis. Cre recombinase activity
irreversibly excises a stop codon in R26R reporter mice thereby
activating constitutive LacZ expression from the Rosa locus. Cre
activity initiates in the caudal region of the embryo by E10 (A). 
additional Cre-mediated excision occurs until between E14.5 and
E 15.5 when the type I collagen promoter becomes activated in
relation to the formation of connective tissues (A&B). Histological
sections of embryos at E12.5 and , E14.5 stained with X-gal and
counterstained with eosin reveal the dramatic induction of Cre
recombinase activity in developing connective tissues (B).
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Figure 3: Cre-mediated excision of Mdm2 in the caudal region
of the embryo prior to E10 results in loss of tissue. The defect is
visible by E10.5 (left panels), and ultimately results in failed tail
formation and a dermal invagination at the site of tissue loss (right
panels).
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Figure 6.4: Activation of the Coll-Cre transgene in the caudal region of
Mdm2 floxflx mice results malformation of the caudal elements of the axial
skeleton, including the absence of tail vertebrae. Coll-Cre Mdm2 flax/flax
(MT) mice fail to form mineralized vertebral bodies in comparison to ColI-
Cre Mdm2+/+ (WT) mice (arrows). The cartilaginous vertebrae in mutant
mice appear to have fused (arrows) and lack an ossification center.
Cartilage is stained blue with alcian blue and bone red with alizarin red.
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Figure 6.5: Tissue loss resulting from Mdm2 deletion is due to
apoptosis. Saggital sections (top and center panels) of WT E10.
embryos showing segmented somites (arrows) and dorsal root
ganglia (arrowheads). MT embryos lack developing neural tissue
(arroweads) leaving somites externalized (arrow). TUNEL staining
of above sections reveals a marked increase in the number of
apoptotic cells in MT embryos (lower panels).
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Excision of Mdm2 in Skeletal Tissues Results in Impaired Bone Formation
Despite cellular loss in the caudal portion of the embryo in response to an early activation
of the Coll-Cre trans gene, the appendicular skeleton and bones of the skull were
unaffected by the initial Cre activation. Activation of the Coll-Cre transgene in the limbs
and skull did not occur until the latter half of gestation (beginning at E14.5). These
skeletal elements were more porous in mutant animals (Figure 6. A) and all
appendicular bones examined were shorter in comparison to wildtype littermates (Figure
A&B). Further, appendicular bones from mutant animals showed significantly less
mineral deposition than wildtype littermates, as assessed by silver nitrate staining (Figure
8). These findings indicate that Mdm2 loss in developing skeletal tissues negatively
affects multiple parameters of bone quality. Unlike the consequences of Mdm2 deletion
in undifferentiated progenitor cells after Coll-Cre induction, skeletal elements from
mutant embryos exhibited no increase in apoptotic cell number (Figure 6.9). These
observations led us to examine the growth and differentiation of osteoprogenitor cells 
vivo.
Activation of the Mdm2 Gene is Required for Efficient Osteoblast Differentiation 
Vivo
To understand the underlying cause of the decrease in bone quality in Mdm2
flx/flx/Coll-
Cre mice , we isolated calvarial osteoprogenitor cells from E 19 WT and MT embryos as
well as from R26R/Coll-Cre embryos and visualized the pattern of Cre-mediated excision
in these cultures. Calvarial osteoprogenitors were induced to undergo osteogenic
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Figure 6.6: Coll-Cre Mdm2 floxlflox mice exhibit decreased bone
density and long bone length when compared to Coll-Cre Mdm2+/+
littermates. Skulls of E19 embryos stained with alizarin red for
mineralized bone and alcian Blue for cartilage (A) reveals
extremely porous calvarial bones in mutant mice. Longbones of
MT mice also exhibit increased porosity and a decrease in overall
bone length (B)
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Figure 6.7: Bone-related loss of Mdm2 results in decreased
mineralized and total bone length. Longbones were isolated frm
Coll-Cre Mdm2 floxfllox and Coll-Cre Mdm2+i+ E 19 embryos and
were stained with alizarin red and alcian Blue. Bone lengths for
six embyros of each genotype were taken by measuring length
between chondyles (A) or by measuring the mineralized portion
only (8).
L..
Figure 8: Mdm2 loss in the developing skeleton compromises
mineral deposition. silver nitrate staining for mineral on sections of
E 19 longbones revealing higher mineral content in Coll-Cre
Mdm2+J+ (WT) mice in comparison to Coll-Cre Mdm2 floxlnox (MT)
littermates.
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Figure 6.9: Mdm2 loss in the developing skeleton does not does
not induce apoptosis. Sections of developing ribs (top panels, H&E
stained corresponding to arrowheads on lower panels) from E19
embryos followed by TUNEL staining for apoptotic cells (lower
panels, arrows) reveals no increase in apoptosis in skeletal tissues
lacking Mdm2 (right panels) compared to control samples (left
panels). 13-galactosidase activity (inset) in Coll-Cre R26R mice
marks cells in which recombination has occurred.
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differentiation ex vivo by allowing cultures to proliferate for several days followed by the
addition of ascorbic acid and inorganic phosphate to the media post-confluence. The
addition of ascorbic acid to the cultures osteoprogenitors stimulates post-confluent
proliferation resulting in the formation of multilayered nodules that later 
become
mineralized. Interestingly, Mdm2 was expressed at very low levels in wildtype 
cultues
during the period of proliferation and became strongly activated in post-confluent
cultures during multilayering and extracellular matrix maturation until mineralization
(Figure 6. 10-A). Mutant cultures failed to induce Mdm2 gene expression at any stage of
culture (Figure 6. 10-A), and examination R26R1Coll-Cre cultures indicated that Cre-
mediated recombination of Mdm2 occured exclusively in maturing osteogenic nodules
(Figure 6. 10-B). These results indicate that the increase of Mdm2 gene expression
occured in differentiating osteoblasts within multilayering nodules.
Analysis of both wildtype and mutant-derived osteoprogenitor cultures indicates that
these cells achieved confluence simultaneously (Figure 6. , left panels), and BrdU
incorporation indicated that there were no proliferation defects in mutant cultures prior to
confluence (data not shown). In addition, X-gal staining of R26R1Coll-Cre cultures
indicated that few osteoprogenitor cells had activated the transgene prior to isolation from
the embryo (Figure 6. 10- , left panel). After osteoprogenitor' cells reached confluence
wildtype cultures underwent robust nodule formation, while mutant cultures were unable
to form a significant number of multilayered nodules, and subsequently only a small
fraction of these cells were able to undergo differentiation and activate alkaline
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Figure 10: Mdm2 induction during osteoblast differentiation
occurs in mature cells and is inhibited in cultures derived from
Coll-Cre Mdm2 floxJflox (MT) mice. RT-PCR analysis of Mdm2
messenger RNA levels throughout ex vivo osteoblast
differentiation showing an increase in Mdm2 levels concomitant to
an increase in osteogenic differentiation in Coll-Cre Mdm2+/+
(WT) cells (A). Cultures derived from Coll-Cre Mdm2 flox/flox (MT) do
not exhibit an increase in Mdm2 mRNA. Analysis of I
galactosidase activity in Coll-Cre R26R mice reveals that Cre
activity is inducing recombination primarily in multilayering nodules
of mature osteoblasts (8).
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Figure 6.11: Loss of Mdm2 during osteoblast maturation results in
failure to form osteogenic nodules ex vivo. Cultures of Coll-Cre
Mdm2+/+ (WT) osteoprogenitors undergo post-confluent
proliferation to form alkaline phosphatase secreting osteoblast
nodules that ultimately become mineralized (silver nitrate). 
contrast, Mdm2 floxlflox (MT) cultures reach confluence, but fail to
multilayer and form osteogenic nodules, and subsequently are
unable to secrete alkaline phosphatase or mineralized
extracellular matrix.
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phosphatase activity (Figure 6. , Center panels). Consistent with our in vivo findings
the wildtype osteoblasts ultimately formed heavily mineralized nodules while mutant
cultures failed to deposit significant mineral in the extracellular matrix (Figure 6. , right
panels).
Quantitative analysis of osteogenic gene expression revealed that both wildtype and
mutant cultures activate early osteogenic genes type I collagen and alkaline phosphatase
but gene activity is abrogated in mutant cultures shortly after achieving confluence
(Figure 6. 12). Osteoca1cin, a marker oflate osteoblast differentiation, is not activated in
mutant cultures at any time during the culture period (Figure 6. 12). Since osteoblast
differentiation and expression of these osteoblast phenotypic genes is entirely dependent
on the activity of the Runt-related transcription factor Runx2 (Ducy et al. 1997; Komori
et al. 1997; Otto et al. 1997), we next examined the impact of Mdm2 loss on the activity
of this gene. Interestingly, both Runx2 protein and mRNA levels are lost in cultures
concomitantly with the loss of Mdm2 (Figure 6. 13 A&B). Taken together, our results
indicate that Mdm2 activity is required for post-confluent proliferation of osteoblast
cultures, and that this post-confluent cell division is required for the subsequent
activation of the master osteoblast transcriptional regulator Runx2. Failure of cultures
lacking Mdm2 to activate the Runx2 gene ultimately results in inhibition of osteoblast
differentiation and inactivity of osteoblast phenotypic genes.
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Figure 6.12: Osteoblast phenotypic gene expression is abrogated
after Mdm2 loss in ex vivo cultures of osteoprogenitor cells. ColI-
Cre Mdm2+/+ (WT) osteoblasts initially activate alkaline
phosphatase and Type I collagen gene expression at confluence,
followed by a dramatic induction of osteocalcin gene expression
prior to mineralization. Mdm2 flo)(lox (MT) cultures induce alkaline
phosphatase and Type I collagen gene expression at confluence,
but are ultimately unable to support the activity of these genes or
osteocalcin after Mdm 2 loss.
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Figure 6.13: Mdm2 activity is required for activation of the
osteogenic master transcriptional regulator, Runx2. Quantitative
RT -PCR analysis of Runx2 expression demonstrates that after
Mdm2 loss in osteogenic nodules in Mdm2 flox/flax (MT) cultures,
these cells cannot support the increase in Runx2 gene activity
observed in Coll-Cre Mdm2+/+ (WT) (A). The lack of Runx2 gene
activity results in dramatic loss of Runx2 protein in Mt cultures (B).
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Inhibition ofp53 Activity by Mdm2 is Requiredfor Osteogenic Diferentiation
Given the prevailing role of Mdm2 as a negative regulator of p53 , we hypothesized that
the induction of Mdm2 during formation reflected a requirement for a decrease in p53
activity to facilitate post-confluent cell division. Interestingly, examination of total p53
levels revealed no change in total p53 protein in mutant cultures. (Figure 6. , upper
panel). Upon closer examination of activated p53 using a phospho-Ser15 specific
antibody, a marked induction in P-Ser15 p53 was observed in mutant cultures when
compared to Mdm2-retaining cultures (Figure 6. , lower panel). This increase in
phosphorylated p53 corresponded to a more rapid and stronger induction of p21 gene
activity during osteoblast differentiation, but this was not associated with an increase in
apoptosis (Figure 6. 15-A&B). These findings support the hypothesis that Mdm2 activity
in osteoblasts regulates p53 activity, and suggest that this regulation occurs at the level of
post-translational modification ofp53.
To determine definitively whether the effects of Mdm2-10ss on osteoblast differentiation
are due exclusively to an excess of p53 activity, we examined differentiation of
osteoprogenitor cells harvested from calvaria of p53-/- MdmT/- mice.
Mice lacking both p53 and Mdm2 were phenotypically normal at the time of calvaral
osteoprogenitor cell harvest (E 19) (Figure 6. 16). These embryos did not exhibit the
shortening of limbs and increased porosity observed in Mdm2
flx/flxColl-Cre animals
suggesting that unregulated p53 is in fact the cause of the defective bone formation seen
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Figure 6.14: Mdm2 loss during osteob ast differentiation results in
an increase in p53 activation. Analysis of p53 protein levels in ex
vivo osteoblast cultures from Coll-Cre Mdm2+/+ (WT) or Mdm2
flaX/flax (MT) cultures showing no difference total p53 levels (A).
Actiated p53 (phospho-serine 15) is increased in the absence of
Mdm2 (8).
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Figure 6.15: Mdm2 loss results in increased p21 gene activity not
apoptosis in calvarial osteoblast cultures lacking Mdm2. TUNEL
staining of post-confluent osteogenic cultures reveals no significant
apoptotic events in either Wt or Mt cells (A). Activity of the cell
cycle inhibitor p21 was analyzed by q-RT-PCR analysis in primary
osteoblast cultures (B). Coll-Cre Mdm2+/+ (Wt) cells exhibit a
gradual increase in p21 messenger RNA levels reaching maximal
expression in mineralized cultures. Coll-Cre Mdm2 flox/flox (Mt)
cultures dramatically increase p21 activity levels two-fold over Wt
cultures between confluence and extracellular matrix formation.
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Figure 16: Concomitant deletion of both p53 and Mdm2
rescues dysplasia of the axial skeleton and the retardation in
long bone growth observed in Coll-Cre Mdm2 flax/flax embryos.
Skeletons from E 19 mice were stained with alizarin red and alcian
blue. Axial skeletons (A) and long bones (8) were indistinguishable
between p53 null and p53/Mdm2 null animals.
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in Mdm2flx/flxColl-Cre skeletons. The loss of p53 in the absence of Mdm2 also rescues
the dysplasia of the axial skeleton observed in Coll-Cre Mdm2 flox/flox embryos
demonstrating that the apoptotic event underlying that defect was due to de-regulation of
p53.
We next isolated calvarial osteoblasts from both p53- and p53- - Mdm2"
/- 
mice and
induced these cells to differentiate ex vivo. These cultures achieved confluence
simultaneously when plated at equal density and underwent robust post-confluent
proliferation (Figure 6. 17, toluidine blue) resulting in dramatic extracellular matrix
formation (Figure 6 , alkaline phosphatase) and mineralization (Figure 6. , silver
nitrate). Furher, these cultures had restored Runx2 activity and subsequently exhibited
normal expression of osteoblast phenotypic genes (Figure 6.18 and 6. 19). Surprisingly,
cultures lacking p53 or both p53 and Mdm2 were stil capable of strong p21 induction
indicating that in this system, p21 expression is not dependent on p53. Mdm2 was also
strongly induced during p53 null osteoblast differentiation, again indicating that p53-
independent mechanisms induce Mdm2 gene expression in the osteoblast. Taken
together these results further suggest that the earlier induction of p21 observed in the
absence of Mdm2 is not responsible for the failure of these cultures to undergo post-
confuent cell division. Our findings demonstrate that loss of Mdm2 during osteoblast
differentiation results in an inappropriate activation of p53 ultimately leading to a failure
to undergo post-confluent proliferation prior to differentiation. The regulation of p53 by
Mdm2 is therefore critical for proper skeletal development and disruption of the p53-
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Mdm2 regulatory loop ultimately results in failure to activate the master osteogenic
transcriptional regulator, Runx2, whose activities are required for osteoblast
differentiation and bone formation.
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Figure 6.17: Primary osteoblasts lacking either p53 or both p53
and Mdm2 undergo robust proliferation in post-confluent culture.
Calvarial osteoblasts were isolated from p53- or p53- - Mdm2-
mice and plated at even densities. Cultures achieved confluence
simultaneously (toluidine Blue) and were induced to differentiate
(alkaline phosphatase). Both p53- and p53- Mdm2- - cultures
formed large amounts of mineralized tissue ex vivo (silver nitrate)
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Figure 18: Primary osteoblasts lacking either p53 or both p53
and Mdm2 exhibit normal bone-specific gene expression patterns.
aRT -PCR analysis of osteogenic cultures showing dramatic
induction of bone-specific genes in the absence of p53.
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Figure 6. 19: Primary osteoblasts lacking either p53 or both p53
and Mdm2 support Runx2 and p21 gene activity. Messenger RNA
levels in these cultures reveal normal Runx2 expression in the
absence of p53. The p21 gene is induced despite the absence of
p53 in primary osteoblast cultures.
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DISCUSSION
While maintenance of the Mdm2-p53 autoregulatory loop has been shown to be critical
for implantation of developing mouse embryo (Jones et al. 1995), the importance of
Mdm2 in controllng p53 during normal tissue development is not known.
demonstrate here for the first time that deletion of Mdm2 has tissue-specific
consequences that are ultimately a result of deregulated p53 activity. We have achieved
biphasic deletion of a Mdm2 conditional allele (Steinman and Jones 2002) during
embryogenesis by activation of aCre recombinase-containing transgene controlled by the
activity of the type I collagen promoter (Coll-Cre). This promoter is activated early in
both mesenchymal and neural progenitor cells in a localized region of the developing
embryo. Activity of this transgene in mice homozygous for an Mdm2 conditional allele
resulted in widespread apoptosis. This finding is consistent with prior studies
demonstrating that Mdm2 loss in the pre-implantation mouse embryo results in lethality
due to apoptosis (Jones et al. 1995; de Rozieres et al. 2000; Chavez-Reyes et al. 2003)
and suggests that such undifferentiated embryonic cells preferentially undergo apoptosis
rather than induce cell-cycle arrest in response to p53 hyperactivity.
Lineage tracing to mark cells that have undergone Cre recombination revealed a second
more widespread activation of the Coll-Cre transgene later during development (E 13 .
EI4.5) in relation to the differentiation of connective and skeletal tissues. Strong
transgene activity was observed in osteoblasts and bones where Mdm2 loss led to
impaired bone formation. Bones of Mdm2
flox/flox Coll-Cre mice were shorter, more
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porous, and exhibited decreased mineral content in comparison to wildtype animals due
to inefficient activation of osteoblast specific genes responsible for secretion and
mineralization of extracellular matrix. Coll-Cre Mdm2 
flox/fox primary calvarial pre-
osteoblasts inactivate Mdm2 in response to activation of type I collagen in post-confluent
cultures resulting in an increase of phosphorylated p53 protein levels and p21 gene
expression. After post-confluent inactivation of Mdm2 , these cultures fail to undergo the
proliferation required to multilayer and form osteogenic nodules. Consequently, Runx2
and the array of osteogenic genes regulated by Runx2 fail to become induced thereby
inhbiting osteoblast differentiation.
We initially hypothesized that the inhibition of post-confluent proliferation was due to
increased p53 activity and subsequent induction of p21 resulting in cell-cycle arrest. To
address this hypothesis, we examined osteogenic differentiation in the absence of both
Mdm2 and p53. The concomitant loss of both of these proteins rescues the defects
observed in Mdm2flox/flox Coll-Cre mice, demonstrating that p53 activity is indeed the
underlying cause of the observed defect. Interestingly however, p21 gene expression is
stil dramatically upregulated during osteogenic differentiation in both p53 null and
p53/Mdm2 double null osteoblasts, indicating that p21 is not responsible for the
inhibition of post-confluent proliferation and subsequent skeletal abnormalities observed
in Mdm2flox/flox Coll-Cre mice. Further, this result demonstrates that p21 induction is not
p53-dependent during osteogenesis , consistent with the findings of Funato et al. (Funato
et al. 2001) who demonstrate that the observed p21 induction during osteoblast
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differentiation is mediated by E2A and co-factor CBP and that this induction is p53-
independent.
Taken together, our findings indicate that maintenance of the Mdm2-p53 autoregulatory
loop is required for skeletal development and suggest that the induction of Mdm2 during
osteogenic differentiation acts to suppress p53 activity. Furthermore our results
demonstrate that in the absence of Mdm2 , increased p53 activity prevents pre-osteoblasts
from undergoing proliferation prior to osteogenic differentiation. Our findings suggest
that this period of proliferation is a pre-requisite for osteogenesis, as cultures that lack
Mdm2 and fail to enter this proliferative period are unable to activate the Runx2 gene
and therefore are unable to undergo osteogenic differentiation. The major novel finding
emerging from these studies is that there is a requirement for an intact p53-Mdm2
autoregulatory loop during normal tissue formation in the developing mouse embryo.
Furher, our findings suggest that Runx2 may act as a link between proliferation and
differentiation of an osteoblast (Pratap et al. 2003), as Runx2 gene activity is inextricably
linked to the fidelity of the p53-Mdm2 autoregulatory loop.
The results presented in this study indicate that the use of Mdm2 inhibitors as a treatment
to induce growth inhibition in malignant tumors may have detrimental consequences on
the formation and maintenance of skeletal tissue and the effects of such compounds
should be carefully assessed prior to administration to human subjects.
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The Runx family of transcriptional regulators is well known for the tissue-specific roles
Runx proteins play in cell fate determination and progression of differentiation during
mammalian embryogenesis. Evolutionary pressure demanded that Runt homology
proteins develop distinct functions in divergent eukaryotic species. In mammals, the
three Runx genes exhibit sequence homology and some fuctional redundancy but their
expression is highly tissue-specific in order to accommodate cell-type specific functions.
These three mamalian Runx genes evolved from a single gene that initially occurred in
bilaterians where it is involved in body patterning and cell fate determination. In
chordates , the Runx genes evolved a second promoter and then underwent gene
duplication (Rennert et at' 2003). While evolutionary pressures demanded that the
mammalian Runx factors have distinct, tissue-specific functions, these genes have
conserved protein motifs and regulatory elements in their promoter regions, suggesting
that a common fuction for Runx factors may persist in vertebrates. Studies from many
groups examining Runx expression have identified several tissues that support the
expression of multiple Runx genes, including early embryonic, undifferentiated
mesenchymal progenitor cells (Lengner et al. 2002; Stricker et al. 2002; Taniuchi et al.
2002; Yamashiro et al. 2002). These observations support a hypothesis that the Runx
proteins may play redundant roles early during development.
At its onset, the research summarized in this dissertation was aimed primarily at
understanding the regulation of the Runx2 gene in osteoblast lineage cells, however it
rapidly became clear that Runx2 regulation was distinct from that of typical osteoblast-
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specific genes. We initially generated transgenic animals in which the 
Runx2 PI promoter
controls expression of the LacZ reporter gene. Surprisingly, our findings demonstrated
that this promoter region is inactive in osteoblast lineage cells known to express 
Runx2
and is unresponsive to the osteogenic BMP2 signal, suggesting that the osteoblast-related
locus control region of the Runx2 gene lies outside of the proximal 3 kb used in these
studies. Interestingly, activity of this promoter was strongly induced as early as E8.
during gestation in progenitor cells surrounding the notochord, consistent with previous
observations of endogenous Runx2 gene activity in the notochord prior to skeletogenesis
(Otto et al. 1997). This finding suggested that Runx2 plays a role in undifferentiated
progenitor cells that are not destined to undergo osteogenesis and that the 
Runx2 gene is
responsive to signaling pathways active early during the development of the mamalian
embryo. Interestingly, Runx2 trans gene expression in these mice displayed a pattern
reminiscent of the segmented expression seen for runt 
transcripts in drosophila embryos
(Gergen and Wieschaus 1985; Gergen and Wieschaus 1986).
These initial observations led to the investigation of pathways upstream of the 
Runx2
gene in mesenchymal progenitor cells and further, led us to examine the function of
Runx2 in these early embryonic tissues. Based on the segmented expression of the
Runx2 PI promoter in developing somites at E9, several candidate factors were examined
for their effect on Runx2 gene activity. Ultimately, the homeodomain factor Nkx3.2 was
identified as a repressor of the Runx2 PI promoter that interacts with a consensus Nkx3.
binding sequence in the minimal promoter region. Chromatin immunoprecipitation
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analysis further demonstrated that Nkx3. 2 binds the Runx2 promoter in C3HI0Tl/2
mesenchymal progenitor cells in order to suppress Runx2 expression. During
chondrogenic differentiation of these C3H lOT 1/2 cells we observed a sharp decrease in
Runx2 expression that coincided with an equally intense activation of the Nkx3.2 gene
suggesting that repression of Run2 played a role in the chondrogenic commitment of a
progenitor cell. Overexpression studies demonstrated that Runx2 could in fact inhibit
activation of the chondrocyte-specific program of gene expression if it is not adequately
repressed. Interestingly, these cells also express Runx 1 and, to some extent Runx3, but
these genes exhibit dissimilar expression patterns during chondrogenesis and their
promoters do not contain the Nkx3.2 consensus sequence found in the Runx2 promoter.
To examine a potential functional cooperation between Runx1 and Runx2 in the
mesenchymal progenitor cell, we developed a culture system in which chondrogenic
differentiation of mouse embryonic fibroblasts is promoted through stimulation with
BMP2 in high-density micromass cultures. Like C3HI0Tl/2 cells, MEFs differentiate
along the chondrogenic lineage , expressing stage-specific chondrocytic genes and
undergoing hypertrophy to form a mineralized extracellular matrix. MEFs and
C3H10Tl/2 demonstrate very similar patterns of Runxl and Runx2 expression. Runx2 is
suppressed at the onset of chondrogenesis only to become strongly induced in late-stage
chondrocytes where it plays a well-characterized role that it shares with Runx3 in
promoting hypertrophy and mineralizing the extracellular matrix (Yoshida et al. 2004).
Conversely, Runxl levels were strongly induced at the onset of chondrogenic
167
differentiation, primarily in response to the three-dimensional environment of the
micromass cultures (Figure 4. , T=O) and then declined as cultures entered final stages
of chondrocyte hypertrophy. The distinct patterns of Runx 1 and Runx2 expression
during chondrogenesis suggest that these two factors may play non-redundant functions
during chondrogenic differentiation. We therefore utilized the MEF cell culture model to
analyze chondrogenic differentiation in the absence of Runxl or Runx2. Consistent with
our previous findings, Run2 null MEFs exhibited increased carilage formation ex vivo.
Runx1 null MEFs, while still able to complete the program of chondrogenic
differentiation, formed smaller carilaginous nodules ex vivo. This result suggests that the
increase in Runxl levels at the onset of chondrogenesis supports some proliferative
expansion prior to differentiation. Together, these findings indicate that Runx1 and
Runx2 play distinct roles in chondrogenic differentiation. We note that co expression of
Runx 1 , 2, and 3 in undifferentiated cells in the early embryo may stil be masking
common functions of the Runx factors. The elucidation of these functions may
ultimately demand deletion of all three factors.
In addition to the role of Runx genes in fate determination, these factors have also been
closely linked to cell growth control. Translocations of the Runx 1 gene result in
hyperproliferation and a block in the differentiation of myeloid progenitor cells (Yergeau
et al. 1997; Zent et al. 1997), Deletion of Runx3 results in gastric cancer in mice and men
(Yergeau et al. 1997; Zent et al. 1997), pro-viral insertions that activate the Runx2 gene
cooperate with myc in virus-accelerated lymphomas (Stewart et al. 1997) and Runx has
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been shown to inhibit proliferation in osteoprogenitor cells, a novel role distinct from its
function in activation of osteoblast phenotypic genes (Pratap et al. 2003). Based on these
findings, we chose to examine the interrelationship between Runx2, bone formation, and
the Mdm2-p53 autoregulatory loop. It is thought the p53 tumor suppressor undergoes
continual degradation through the actions of Mdm2 during normal cell proliferation.
Upon cellular insult, such as DNA damage, Mdm2 degradation of p53 is terminated
allowing for p53 accumulation and activation (Alarcon-Vargas and Ronai 2002; Vousden
and Lu 2002; Chene 2003). Active p53 can then induce cell cycle arrest or apoptosis;
how p53 makes this decision is not understood. While p53 inactivationlMdm2
hyperactivation commonly result in tumorigenesis, the consequences of p53
hyperactivation/dm2 inactivation are not known as mice lacking Mdm2 die around E5
due to p53-dependent apoptosis (Jones et al. 1995; Montes de Oca Luna et al. 1995; de
Rozieres et al. 2000). Furher, exogenous p53 overexpression in vivo has invariably led
to lethality. It has been suggested that a hypermorphic p53 allele that results in increased
p53 tetramer stabilization leads to premature ageing and osteoporosis in vivo (Tyner et al.
2002). These findings led us to examine the effects of tissue-specific Mdm2 loss on bone
formation and Runx2 activity.
By utilizing the Cre-lox system for conditional gene deletion, we were able to inactivate
Mdm2 in immature osteoblasts in response to activation of a transgene containing the Cre
recombinase coding sequence under transcriptional control of the type I collagen
promoter. Surprisingly, deletion of Mdm2 in the pre-osteoblast did not result in
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apoptosis in vivo or in vitro as it does earlier during murine embryogenesis. Instead
Mdm2 
floxljox Coll-Cre Transgenic mice displayed decreased limb length and bone
mineral content. Ex vivo calvarial pre-osteoblast differentiation experiments
demonstrated that the collagen-Cre trans gene is active in multilayering osteoblast
nodules, and that loss of Mdm2 in these cells prevents them from undergoing the post-
confluent proliferation required for nodule formation. These cultures fail to activate
Runx2 and the osteoblast phenotypic program of gene expression. These findings
demonstrate that fidelity of the Mdm2-p53 regulatory loop is critical for proliferation of
the pre-osteoblast and that this proliferation is, in tu, a pre-requisite event for activation
of Runx2 gene expression. Thus, this study establishes the interconnectedness of cellular
proliferation and differentiation and demonstrates that Runx2 gene activity is dependent
on the Mdm2-p53 autoregulatory loop.
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Table I: PCR Primers
Primer Name
Run2
Runl
Nkx3.
Sox9
collagen IaI
colla en II
colla en X
osteocalcin
alkaline Phos.
Ihh
Mdm2 (exon12)
Cre Recombinase
GAPDH
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